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ABSTRACT 
 
DAILY NOCTURNAL MELATONIN SUPPLEMENTATION IN 
PERIMENOPAUSAL WOMEN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED PILOT STUDY EXAMINING THE EFFECTS OF MELATONIN ON 
BONE HEALTH AND QUALITY OF LIFE 
 
By 
Mary P. Kotlarczyk 
December 2011 
 
Dissertation supervised by Paula A. Witt-Enderby, Ph.D. 
Objective:  The purpose of this pilot study was to assess the effects of nightly 
melatonin supplementation on primary endpoints of bone health and secondary endpoints 
of quality of life in perimenopausal women.   
Methods: A total of 18 perimenopausal women were randomized to receive 
melatonin, 3 mg p.o., (n=13) or placebo (n=5) nightly for six months.  Bone density was 
measured by calcaneal ultrasound.   Osteocalcin (OC), a bone formation marker, and 
amino-terminal cross-linking telopeptide of type I collagen (NTX), a bone resorption 
marker, were measured in serum samples taken bimonthly to assess changes in bone 
turnover.  Participants completed the Menopause-Specific Quality of Life-Intervention 
(MENQOL) and Pittsburgh Sleep Quality Index (PSQI) questionnaires before treatment 
and after six months.  Subjects kept daily diaries recording menstrual cycling, well-being, 
and sleep patterns.  
 v 
Results:   No significant differences in bone density or bone turnover markers 
were found with melatonin supplementation; however, there was a time-dependent trend 
in the melatonin group towards an NTX:OC ratio of 1:1.  A ratio of 1:1 could be an 
indication of the ability of melatonin to balance bone resorption and bone formation to 
maintain bone mass.  Melatonin had no effect on vasomotor, psychosocial, or sexual 
MENQOL domain scores after six months of nocturnal supplementation.  However, 
women taking melatonin had significant improvement in physical MENQOL domain 
scores compared to placebo (-0.6 ± 0.8 and 0.1 ± 0.5, respectively).  There were no 
significant changes in PSQI score or average number of hours slept with melatonin 
treatment.  Analysis of menstrual cycling data showed women in the melatonin group had 
significantly fewer periods (4.3 ± 0.6, n = 10 melatonin; 6.5 ± 0.3, n =4 placebo; mean ± 
SEM) and longer days between periods (51.2 ± 11.4, n = 10 melatonin; 24.1 ± 0.9, n = 4 
placebo) but showed no difference in duration of bleeding.  Melatonin supplementation 
was well-tolerated. 
Conclusions:  Melatonin may have the ability to regulate serum markers of bone 
metabolism, indicating a potential role for melatonin in restoring imbalances in bone 
remodeling and prevention of bone loss. The improvement in quality of life with 
melatonin indicates supplementation may be beneficial for women experiencing physical 
symptoms of menopause.  Further investigation into how melatonin impacts bone health 
and quality of life is warranted. 
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INTRODUCTION 
Perimenopause 
A women‟s reproductive health changes throughout her lifetime.  The typical 
female reproductive cycle consists of three phases: the follicular phase, ovulation, and the 
luteal phase.  During the follicular phase, oocyte-containing follicles develop in the ovary 
and secrete estradiol.  Estradiol acts at the hypothalamus to trigger release of 
gonadotropin-releasing hormone (GnRH), which activates receptors on the anterior 
pituitary gland. Activation of these receptors induces secretion of follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH).  FSH stimulates ovarian follicles to 
develop further, with one dominant follicle becoming destined for ovulation.  The 
follicles continue to release estradiol.  Low levels of estradiol inhibit secretion of LH 
from the pituitary.  When estradiol reaches a threshold level, however, it stimulates the 
release of LH.  The resulting surge in LH immediately precedes the release of the mature 
egg from the follicle.  During ovulation, the follicle ruptures and releases the egg from 
the ovary.  The remainder of the follicle develops into the corpus luteum, which secretes 
estradiol and progesterone.  During the luteal phase, the rising progesterone acts in the 
uterus to thicken the endometrial lining for implantation.  Estradiol and progesterone 
exert negative feedback on the anterior pituitary to lower levels of FSH and LH.  
Towards the end of the luteal phase, the corpus luteum atrophies and estradiol and 
progesterone levels diminish.  The loss of negative feedback on FSH secretion results in 
rising levels of FSH.  If no fertilization occurs, the endometrial lining is shed during 
menstruation, and the cycle begins again.
1
  As women age, there is a decline in ovarian 
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function due to depletion of follicle stores.  An increasing amount of cycles are 
anovulatory in which no egg is released.  The changes in ovarian function result in 
irregular patterns of endocrine hormone secretion.  These variable changes continue until 
there is complete cessation of the menstrual cycle (menopause). 
The transition through menopause is unique to each woman; however, the 
majority of women experience a change from regular menstrual cycling to irregular 
menstrual periods and finally to cessation of menstruation.
2
  According to the Stages of 
Reproductive Aging Workshop (STRAW), the main reproductive stages are classified 
into three phases: reproductive, menopausal transition, and postmenopause.
3
  Stages are 
described in terms of menstrual cycling and characteristic endocrine changes.  
 
Figure 1: Stages of Reproductive Aging.  The diagram above illustrates the main phases in 
female reproductive aging according to the STRAW meeting including the reproductive stage 
characterized by normal menstrual cycling, the menopausal transition (perimenopause) stage 
identified by irregular cycling, and the postmenopause stage when there is cessation of the 
menstrual cycle.  Figure reprinted from Soules MR, Sherman S, Parrott E, et al. Stages of 
Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med. Nov 
2001;10(9):843-848, Copyright 2001, with permission from Mary Ann Liebert, Inc. publishers. 
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As illustrated in Figure 1, the reproductive phase encompasses the time from 
menarche to the onset of irregular menstrual cycles, which usually occurs when a women 
is in her middle to late forties.  The menopausal transition phase, including the 
perimenopause stage, is characterized by variable menstrual cycling length and intervals 
of amenorrhea (absence of a menstrual period).  Perimenopause is defined as the stage 
immediately before menopause and extending to the first year after menopause.  The 
postmenopause phase is the year after the final menstrual period to the end of life.   
As noted, there is some overlap in the definition of stages, particularly concerning 
the year after the final menstrual period.  There is also ambiguity as to the definitive 
starting and ending points to each stage.  In this study, we chose to study melatonin 
supplementation in perimenopausal women.  There is no clinical test that indicates the 
start or end of the perimenopausal state.  An extensive review of the literature concluded 
that perimenopause is characterized not by declining estrogen levels as traditionally 
accepted; instead, perimenopausal women have periods of high estrogen compared to 
premenopausal women.
4
  Estrogen and FSH levels fluctuate and are typically higher in 
perimenopausal women.
5
  Due to the frequent fluctuations in reproductive hormones, 
perimenopause is often accompanied by symptoms such as difficulty sleeping, vaginal 
dryness, and vasomotor symptoms like hot flashes.
6, 7
  Signs of bone loss also begin to 
occur during perimenopause, indicating the deterioration of bone seen in postmenopausal 
osteoporosis may begin earlier than the onset of menopause.
8-10
 
Osteoporosis  
Osteoporosis is a bone disease that develops when there is an imbalance in bone 
remodeling.  Bone is constantly changing, undergoing a process of breakdown and 
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rebuilding.  The remodeling process is under the control of two types of bone cells: 
osteoclasts and osteoblasts. Osteoclasts are responsible for the resorption of old bone, 
creating cavities, which are then replaced with new bone matrix by osteoblasts (Figure 2).   
 
Figure 2: The bone remodeling process.  Osteoclasts break down bone in the process of 
resorption, creating cavities.  Bone-forming osteoblasts fill in the areas of bone loss to complete 
the remodeling process.  Figure reprinted from Doheny MO, Sedlak CA, Estok P, Poirier V. DXA 
valuable for bone mineral density testing. Nurse Pract. Nov 2003;28(11):44-49, Copyright 2003, 
with permission from Wolters Kluwer Health, Inc. 
An imbalance in the activity of osteoclasts and osteoblasts can lead to the development of 
osteoporosis.
11
  It is believed that in osteoporosis, osteoclast activity outpaces osteoblast 
activity, such that more bone is broken down than is being formed.  This imbalance in 
bone remodeling leads to an overall loss of bone mass and an increased risk of fracture.  
In 2005, fractures resulted in $17 billion of direct medical costs. Costs are estimated to 
exceed $20 billion by 2025; therefore, research into osteoporosis prevention is crucial.
12
   
Role of reproductive hormones in osteoporosis 
Women in particular are at greater risk for osteoporosis, accounting for 80% of 
Americans diagnosed with osteoporosis.
13
  The increased incidence of osteoporosis in 
women has largely been attributed to declining levels of estrogen during the menopausal 
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transition as decreases in circulating estrogen coincide with rapid bone loss and estrogen 
replacement therapy is protective against bone loss.  Emerging research has shown the 
importance of other reproductive hormones, which may also play a role in the 
development of postmenopausal osteoporosis, namely FSH and progesterone.   
FSH levels are high during perimenopause, a time of significant bone loss in 
women.  Results from the Study of Women‟s Health Across the Nation (SWAN) 
demonstrate a negative correlation between FSH levels and markers of bone metabolism 
in premenopausal and early perimenopausal women.
14
  A study by Sun et al. showed 
transgenic mice with reduced FSH levels but with functional reproductive systems had an 
increase in trabecular bone mass and a decrease in tartrate-resistant acid phosphatase, a 
serum marker of bone resoprtion.
15
  In vitro experiments showed functional FSH 
receptors on human osteoclasts but not osteoblasts.  The authors postulate that high levels 
of FSH may increase bone resorption through activation of FSH receptors on osteoclasts. 
15
  The direct influence of FSH on bone metabolism is of some debate, especially given 
the results of a recent study in which suppression of FSH in postmenopausal women did 
not reduce markers of bone resorption.
16
  To remove any confounding influences of 
estrogen on bone, women in both the control and treatment group were given an 
aromatase inhibitor to decrease estrogen levels.  Contrary to the study by Sun et al.
15
,  
reducing FSH levels did not reduce levels on bone resorption markers or increase 
markers of bone formation.
16
  Nevertheless, there is evidence to support a relationship 
between FSH and bone metabolism either through direct activation of FSH receptors on 
osteoclasts to stimulate bone resorption
15
 or via the modulatory effects of FSH on 
hormones such as estrogen and progesterone.
16
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A recent review by Seifert-Klaus and Prior details the evidence supporting a role 
for progesterone in bone health.
10
  In fact, several in vitro studies show treatment with 
progesterone can increase proliferation of human bone cells
17
, with proliferative effects 
being enhanced with co-administered of estradiol.
18, 19
  The fluctuation in estrogen, FSH, 
and progesterone levels occurring during perimenopause may contribute to the 
deterioration of bone mass.  Research demonstrating the possible roles of FSH and 
progesterone in bone health indicate the need to examine not only estrogen but other 
reproductive hormones when considering the pathology of postmenopausal osteoporosis.   
Current Osteoporosis Treatments 
To prevent the bone loss associated with menopause, it is recommended that 
women have adequate daily intake of calcium and vitamin D.  Even with calcium and 
vitamin D supplementation, women are often prescribed medication to curb bone loss 
associated with menopause. Most prescription therapies are targeted at inhibiting bone 
resorption. These include agents such as calcitonin, bisphosphonates, selective estrogen 
receptor modulators (SERMs), and more recently the receptor activator of NF-κB ligand 
(RANKL) inhibitor denosumab.  The parathyroid hormone (PTH) analog teriparatide is 
the only FDA approved osteoporosis therapy that increases formation of new bone. 
Calcitonin is an endogenous hormone that acts directly on receptors on osteoclasts 
to decrease bone resorption.  Calcitonin is approved for the treatment of postmenopausal 
osteoporosis 5 years after menopause; however, the development of newer drugs has led 
to a decline in calcitonin usage.
20
  Bisphosphonates are the most widely prescribed 
therapy for prevention and treatment of postmenopausal osteoporosis.
21
  Bisphosphonates 
are attracted to areas of high bone remodeling based on their ability to associate tightly 
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with hydroxyapatite, a main mineral component of bone.  During bone remodeling, 
osteoclasts take up bisphosphonate molecules on the bone surface.  Bisphosphonates 
induce apoptosis of osteoclasts to reduce bone resorption.
22
  While effective at preventing 
bone loss and reducing fracture risk, bisphosphonate usage is not without side effects. 
Women taking bisphosphonates have increased incidence of osteonecrosis of the jaw.
23
  
Oversuppression of bone remodeling may also result in an increase in microdamage to 
bone architecture.
24
  Concern has risen over a possible increase in atypical femur fracture 
with long-term bisphosphonate therapy, although there is conflicting data regarding the 
exact role of bisphosphonates in the occurrence of these fractures.
25
  Although not a 
clinically established guideline, many have suggested bisphosphonate usage be limited to 
a fixed length of time or that patients be given a “drug holiday” to reduce the risk of 
untoward effects.  
Estrogen replacement therapy can protect against the bone loss associated with 
menopause; however, there are health concerns with long-term hormone replacement 
therapy including increased risk of breast cancer and adverse cardiovascular events.
26
  
The selective estrogen receptor modulator (SERM) raloxifene has been developed and 
approved in the United States for both the prevention and treatment of postmenopausal 
osteoporosis.  SERMs possess both agonist and antagonist activity with responses being 
tissue-specific.  Raloxifene binds to the estrogen receptor to modulate estrogen-regulated 
gene transcription.  Depending on the tissue of action and the comodulators present, 
raloxifene can act as an estrogen receptor agonist or antagonist.  Raloxifene acts as an 
estrogen receptor agonist in the bone, resulting in inhibition of osteoclast activity and 
reduction of bone resorption.
27
  While SERMs maintain the beneficial effects of estrogen 
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on bone, unwanted side effects with therapy include hot flashes, vaginal dryness, and 
increased risk of venous thromboembolism.
28
   Side effects such as these can affect 
patient compliance and may limit the duration of treatment.   
Denosumab is a new therapy approved in 2010 for the prevention and treatment 
of postmenopausal osteoporosis. Like bisphosphonates, denosumab decreases bone 
resorption but does not do so through the same mechanism of inducing osteoclast 
apoptosis.  Denosumab is a monoclonal antibody, which binds to RANKL, an osteoclast 
activator, thereby reducing osteoclast activity and bone resorption.  Twice yearly 
injections of denosumab for three years significantly reduced the risk of fracture in 
osteoporotic women.
29
 As this is a new therapy, effects of long-term usage are not yet 
known.   
The parathyroid hormone (PTH) analog teriparatide is effective at increasing bone 
mass by stimulating osteoblasts to form new bone.  Teriparatide is a peptide composed of 
PTH amino acids 1-34.  Parathyroid hormone, like calcitonin, is an endogenous hormone, 
which works to maintain calcium homeostasis.  The action of PTH on bone depends on 
the dose and length of exposure.  Elevated PTH levels over extended periods of time lead 
to activation of osteoclasts and an overall increase in bone resorption.  However, 
intermittent spikes in PTH levels, such as with once or twice daily injections of 
teriparatide, stimulate PTH receptors on osteoblasts to increase activity of osteoblasts and 
increase bone mass.
30
  This anabolic therapy is successful in increasing bone density, 
improving the microarchitecture of the bone, and reducing risk of vertebral and 
nonvertebral fractures.
31
  While PTH therapy is effective, patient compliance can be 
affected by the need for subcutaneous injection.  PTH therapy is limited to two-year 
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duration, at which time antiresorptive therapy is often necessary to maintain bone mass 
developed while on PTH.   
Bone Turnover Markers 
Bone turnover markers (BTMs) are biochemical indicators of bone remodeling 
that are typically measured in blood or urine samples.  Changes in bone turnover markers 
occur more rapidly than alterations in bone mineral density (BMD) as measured by dual-
energy x-ray absorptiometry (DXA). For this reason, biochemical markers of bone 
turnover are gaining favor in clinical research, particularly for monitoring patient 
response to osteoporosis therapies.  Markers of bone formation, indicative of osteoblast 
activity, include: osteocalcin (OC), bone-specific alkaline phosphatase (BAP), 
procollagen type I N propeptide (PINP), and procollagen type I C propeptide (PICP).  
With the exception of BAP, all of these markers are products synthesized by osteoblasts.  
Bone-specific alkaline phosphatase is a membrane-bound enzyme on the osteoblast cell 
surface.  Bone resorption markers reflective of osteoclast activity include: amino-terminal 
cross-linking telopeptide of type I collagen (NTX), carboxy-terminal cross-linking 
telopeptide of type I collagen (CTX), deoxypyridinoline (DPD), pyridinoline (PYD), and 
tartrate-resistant acid phosphatase (TRAP).  NTX, CTX, DPD, and PYD are products of 
type I collagen degradation which are released during bone resorption by osteoclasts.  
TRAP is an enzyme of osteoclast origin.   
Markers of bone turnover can be useful in monitoring responses to therapy. Bone 
turnover markers typically show a decrease within 3-6 months of starting antiresorptive 
therapy with bisphosphonates.
32
  Anabolic therapy with teriparatide also induces rapid 
changes in bone turnover markers.
33
  The pattern and timing of how bone markers change 
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with treatment depend on the main mechanism of drug action.  For example, 
bisphosphonates strongly inhibit osteoclast activity.  Bone resorption markers decline 
early in the treatment period (around three months) while bone formation markers do not 
decrease until approximately four weeks later when there is suppression of overall bone 
turnover.
34
  On the other hand, therapy with the anabolic agent teriparatide significantly 
increases bone formation markers within three months, reflecting the enhancement of 
osteoblast activity.  Bone resorption markers do not rise significantly above baseline until 
approximately six months after beginning teriparatide treatment.
34
  Nevertheless, bone 
markers allow for the assessment of treatment effects within a short period of time and 
reflect the rapid cellular effects of therapy on bone metabolism.  Monitoring fluctuations 
in bone turnover markers can provide more rapid indications of patient compliance with 
medication and the level of response to therapy.  In this study, we utilize OC and NTX to 
monitor changes in bone turnover markers after treatment with melatonin. These markers 
were chosen because they have been utilized in previous studies of bone turnover 
markers of perimenopausal women
8, 9, 14, 35
 and are known to be responsive to treatment 
in postmenopausal women.
36, 37
  In addition, these markers can withstand storage before 
detection which was required due to our rolling enrollment period.  Other markers, such 
as BAP, require more immediate measurement making assessment less conducive for our 
study. 
Melatonin 
The current study examined melatonin supplementation in perimenopausal 
women. Melatonin is an endogenous hormone produced in the pineal gland.  Melatonin 
levels are on a circadian cycle with higher levels found during periods of darkness.  
11 
 
Melatonin is synthesized from serotonin in the pineal gland. Serotonin is acetylated by 
arylalkylamine N-acetyltransferase (AANAT) to yield N-acetylserotonin.  Hydroxyindol-
O-methyltransferase acts on N-actylserotonin to yield melatonin.  Synthesis of melatonin 
is under regulation of multisynaptic pathway originating in the suprachiasmatic nucleus 
(SCN) of the hypothalamus and projecting into the pineal gland. Sympathetic signaling 
through norepinephrine activates α1 and β1-adrenergic receptors on pinealocytes.  
Activation of these receptors results in phosphorylation of transcription factors that 
regulate production of AANAT, the rate-limiting enzyme in the melatonin synthetic 
pathway.  AANAT levels are highest during the dark, driving production of more 
melatonin during this period.
38
   Light acts to depolarize retinal ganglion cells that 
innervate the SCN, blocking sympathetic output to the pineal gland, thereby decreasing 
synthesis of melatonin.
39
  Melatonin levels typically begin to rise at dusk and peak 
around 02:00 hours.
40
  Light exposure at night inhibits the nocturnal increase in plasma 
melatonin and can affect the circadian cycle of melatonin release.
41
  A study comparing 
salivary melatonin secretion in subjects aged 18-45 found a decrease of 0.36 hours in the 
duration of melatonin secretion for every 10 years of age.
42
  Peak levels of melatonin are 
lower in middle-age and older subjects, with levels being as low as one-eighth that of 
young adult levels.
43, 44
  
Melatonin can exert effects through two known mammalian melatonin receptors: 
MT1
 
and MT2.  Both receptors are G-protein coupled receptors and signal largely through 
Gi proteins to decrease cyclic adenosine monophosphate (cAMP) levels.  However, 
signaling pathways initiated by melatonin receptor activation vary depending on the 
tissue of interest. (reviewed by Dubocovich, et al.
45
) MT1
 
and MT2 can also act via Gq 
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proteins to increase intracellular calcium.  MT2 has also been shown to decrease cyclic 
cyclic guanosine monophosphate (cGMP).  Internalization of MT2 receptors on human 
adult mesenchymal stem cells (hAMSCs) may play a role in the differentiation process.  
It has been proposed that desensitized MT2 receptors in hAMSCs can bind to β-arrestin 
proteins creating a scaffold which can interact with proteins in the mitogen-activated 
protein kinase (MAPK) pathway including mitogenic extracellular kinase 1/2 (MEK 1/2) 
and extracellular signal-regulated kinase 1/2 (ERK 1/2) to induce differentiation.
46
  Aside 
from interaction with its receptors, melatonin can exert various effects through its potent 
antioxidant and free radical scavenging capabilities.
47-49
   
Melatonin Effects on Bone  
The relationship between melatonin and bone is well-documented.
50-52
  Melatonin 
and enzymes essential for melatonin synthesis have been found in both mouse and human 
bone marrow cells.
53, 54
  Melatonin levels in bone marrow can be orders of magnitude 
higher than those in peripheral blood.
53
  Removal of the pineal gland (pinealectomy) in 
rats significantly reduces both serum and bone marrow concentrations of melatonin 
compared to control animals.  Exogenous nightly administration of melatonin in drinking 
water resulted in a significant increase in bone marrow melatonin compared to control 
animals, suggesting exogenous melatonin is sequestered in bone marrow.
53
  Both the MT1 
and MT2 melatonin receptors have been found on human osteoblasts.
55-57
   Melatonin 
receptor expression on osteoclasts is unknown.  The presence of melatonin biosynthetic 
enzymes and melatonin receptors in the bone implies a direct role for melatonin in the 
bone environment. Melatonin is thought to act on both osteoblasts and osteoclasts to 
affect changes in bone tissue.  In vitro, melatonin stimulates proliferation of extracted 
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human bone cells
58
 and enhances differentiation of rodent preosteoblast cells into 
osteoblasts.
59
 Differentiation of hAMSCs into osteoblasts is also enhanced with 
melatonin through MT2 receptor signaling.
46, 60
   Chronic treatment of hAMSCs with 
melatonin in vitro significantly enhances expression of alkaline phosphatase, an 
enzymatic marker of stem cell differentiation into an osteoblast, through action of the 
MT2 receptor. The greatest increase in alkaline phosphatase was found to be when 
melatonin receptors were desensitized as measured by a loss in radiolabeled melatonin 
binding and a reduced ability of melatonin to inhibit forskolin-induced cAMP 
accumulation.
46
  Melatonin acting through sensitized receptors also induced mRNA 
expression of osteogenic genes; gene-induction was blocked by treatment with an MT2 
selective antagonist.
60
  These studies demonstrate the capability of melatonin to enhance 
differentiation of mesenchymal stem cells into osteoblasts and induce transcription of 
osteogenic genes through the MT2 receptor. 
In addition to promoting bone formation through actions on osteoblasts, 
melatonin may also regulate osteoclast activity to reduce bone resorption.  Bone 
remodeling is a tightly coupled process.  As illustrated in Figure 3, osteoblasts regulate 
the activity of osteoclasts and bone resorption through the release of RANKL and 
osteoprotegerin (OPG).  RANKL is produced by osteoblasts and binds to RANK 
receptors on osteoclast precursor cells to stimulate differentiation into mature osteoclasts.  
The increase in mature osteoclast number leads to an increase in bone resorption.  In 
order to regulate bone loss associated with osteoclast activity, osteoblasts also release a 
protein called osteoprotegerin which acts as a decoy.  OPG binds to RANKL, preventing 
RANKL from binding to RANK receptors and diminishing maturation of osteoclasts.
61, 62
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Figure 3: Control of osteoclast activation by osteoblasts. Osteoblasts stimulate osteoclast 
differentiation through release of RANKL.  Increase in osteoclast activity leads to an increase in 
bone resorption.  Osteoblasts also regulate OPG release to bind RANKL and prevent RANKL 
binding to RANK receptors.  Figure reprinted from Coetzee M, Kruger MC. Osteoprotegerin-
receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis 
treatment? South Med J. May 2004;97(5):506-511, Copyright 2004, with permission from 
Wolters Kluwer Health, Inc.  
 
In vitro treatment of mouse preosteoblast cells with melatonin increases the protein 
osteoprotegerin and decreases RANKL mRNA transcript.
63
  By increasing release of 
OPG from osteoblasts, melatonin may indirectly inhibit osteoclast activation and reduce 
bone resorption. Melatonin, a potent free radical scavenger, may also inhibit bone 
resorption by neutralizing the free radicals formed by osteoclasts to initiate bone 
catabolism.
52
   
Several in vivo studies demonstrate the association between melatonin deficiency 
and bone disease.  Pinealectomy in chickens induces formation of scoliotic curvature in 
the vertebral column.
64, 65
  Treatment of pinealectomized chickens with melatonin 
reduced the number of animals that developed scoliosis.
66
  Bipedal ambulation of 
C57BL/6J mice results in the development of scoliosis.  These mice inherently have 
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almost no circulating melatonin; however, daily injections of melatonin to restore 
circulating levels prevented scoliosis development in this model.
67
 Interestingly, 
pinealectomy did not produce scoliosis in non human primates
68
; however, these animals 
have the ability to support weight on all four limbs which may reduced stress on the 
vertebral column.  Little human data exists on the effects of melatonin on bone health; 
although, melatonin is thought to play a possible role in the development of adolescent 
idiopathic scoliosis (AIS).  While circulating melatonin levels were not found to be 
different in AIS patients
69
, researchers have found altered melatonin signaling in 
osteoblasts from AIS patients compared to cells from healthy individuals.
56, 70, 71
 
Melatonin had a reduced ability to inhibit forskolin-stimulated increases in cAMP in 
osteoblast cells isolated from AIS patients.
70
  A subgroup of AIS patients showed an 
increased coupling of MT2 receptors to Gs proteins as opposed to Gi as found in non-AIS 
patients.
56
  The exact role of melatonin in AIS remains to be discovered, although MT2-
mediated melatonin signaling in the osteoblasts appears to be a factor in the etiology of 
the disease.
72
 
Changes in melatonin rhythms either through altered length of exposure to light
73
 
or pinealectomy
74
 disrupts markers of bone turnover in rats, underscoring the connection 
between melatonin and bone metabolism. Melatonin may work to increase bone 
formation either directly through action on osteoblast differentiation or indirectly through 
release of OPG to inhibit osteoclast activation and reduce bone resorption. Koyama et al. 
found that melatonin, at pharmacological doses, increased bone mineral density by 36% 
in young mice. Bone mass was also enhanced with melatonin as measured by increases in 
trabecular bone thickness by 19%, and bone volume per tissue volume by 49%.  
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Melatonin reduced parameters related to bone resorption including osteoclast surface 
(74% decrease) and osteoclast number (76% decrease), but treatment had little effect on 
bone formation measures (bone formation rate, mineral apposition rate, osteoid volume), 
indicating action primarily through inhibition of resorption.
63
 Melatonin has also been 
shown to enhance the amount of newly formed bone as measured by fluorescent labeling 
in mice injected nightly with melatonin over 21 days.
55
  Studies in ovariectomized rats, a 
model of postmenopausal osteoporosis, demonstrate the bone protective effects of 
melatonin when adequate amounts of estradiol are given concurrently.
75, 76
  For example, 
ovariectomized rats treated with melatonin nightly in drinking water had an increase in 
bone area of the spine and increased bone mineral content of the tibia and skeleton.  The 
highest increases were seen in rats treated with a combination of nightly melatonin and 5 
day/week injections of estradiol.
76
  There are currently no published human studies 
examining melatonin for the prevention and/or treatment of osteoporosis; however, a 
recent study of nurses with 20 or more years of night-shift work indicated a 37% increase 
in hip and wrist fractures compared to those who never worked at night.
77
  This 
information coupled with the knowledge that melatonin rhythms are shifted
78
 and 
melatonin levels are altered in night-shift workers
79
 suggests a relationship between 
altered melatonin levels and increased risk of fractures.  Investigation into the bone 
protective effects of melatonin in humans and its possible use in osteoporosis is 
warranted. 
Melatonin and Quality of Life 
Aside from potential bone protective effects, melatonin may also improve quality 
of life through improvements in sleep. Administration of 0.3 or 1.0 mg of melatonin to 
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health volunteers decreased sleep onset latency and latency to stage 2 sleep as measured 
by polysomnography; subjects reported no hangover effects the day after treatment.
80
 
Indeed, a meta-analysis of sleep studies found that exogenous melatonin administration 
decreases time to onset of sleep, increases sleep efficiency (percentage of time asleep out 
of total time spent in bed), and increases the duration of sleep.
81
  Melatonin alleviates 
insomnia and improves sleep quality in middle-aged to elderly patients without harmful 
side effects.
82
  Treatment of perimenopausal women with 3 mg oral melatonin nightly for 
6 months resulted in significantly improved mood with treatment compared to placebo 
based on a survey developed by the study investigators.  Many women in the melatonin 
group reported improvements in sleep duration and quality, although results were not 
statistically significant.
83
  Disturbances in sleep are a common symptom reported by 
women during the menopausal transition.
6
  As this population is also at higher risk for 
developing osteoporosis, a supplement such as melatonin may be beneficial at preventing 
further bone loss while also alleviating sleep disturbances and improving quality of life.  
Melatonin and Reproduction 
Melatonin may enhance quality of life in perimenopausal women through 
modulation of reproductive hormones. Melatonin has been established as a regulator of 
reproduction in seasonally breeding animals; however, the role of melatonin in human 
reproduction is not fully elucidated.
84, 85
  The exact mechanisms and role for melatonin in 
reproduction may not be known; however, there is evidence melatonin moderates the 
reproductive cycle at both a neuronal level and at the level of the reproductive organs. 
Women with hypothalamic amenorrhea, a disease characterized by low GnRH levels, 
were found to have higher peak melatonin concentrations and an extended duration of 
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nighttime melatonin release,
86, 87
 implicating melatonin in the regulation of GnRH.  
Indeed, melatonin induces cyclic decreases in steady-state levels of GnRH mRNA levels 
in GT1-7 neuronal cells, a murine cell line capable of secreting GnRH.  The effects of 
melatonin were blocked by coadministration with the nonselective melatonin receptor 
antagonist luzindole.
88
  In addition to regulating mRNA, melatonin suppress GnRH 
secretion in GT1-7 cells.
89
  The actions of melatonin on GnRH appear to be mediated 
through activation of melatonin receptors and the MAPK pathway.
88, 89
 
In addition to effects on GnRH, melatonin has also been implicated in modulate 
of reproductive hormones at the organ level. Melatonin, at concentrations higher than in 
serum, has been found in the ovary, specifically preovulatory follicular fluid.
90, 91
  
Melatonin in the follicular fluid has been hypothesized to play a role in reducing 
oxidative damage and enhancing maturation of mature oocytes for ovulation.
92
 Melatonin 
may also regulate ovarian function through receptor-meditated pathways as melatonin 
receptor mRNA
93, 94
 and binding sites
95
 have also been discovered in ovarian granulosa 
cells. Melatonin receptor mRNA and binding sites have also been identified in human 
myometrium (uterine smooth muscle) biopsies.
96
  In vitro, melatonin sensitizes uterine 
smooth muscle cells to procontractile signals, suggesting melatonin may play an 
important role in preparing the uterus for labor.
97, 98
 
Additional evidence of a role for melatonin in reproductive function includes the 
correlations between melatonin and reproductive hormones. In vitro studies demonstrate 
the ability of melatonin to enhance secretion of progesterone from human granulosa 
cells
94, 99
 and corpus luteum.
100
  Conversely, melatonin has an inverse relationship with 
estrogen such that when estrogen levels are high melatonin levels are low.
101-104
 A 
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negative correlation between melatonin and FSH levels was found in perimenopausal 
women, showing a decrease in melatonin as women transition through menopause.
105
  
Aside from relationships between melatonin and other hormone levels, melatonin may 
interfere with the ability of estradiol to mediate responses through the estrogen 
receptor.
106, 107
  The complexities of how melatonin mediates responses in the 
reproductive system are not well-understood, but the evidence supports a direct role for 
melatonin in the human reproductive system. 
Melatonin Supplementation  
Melatonin is widely available as an over-the-counter oral supplement to relieve jet 
lag and promote restful sleep. Pharmacokinetic studies of oral melatonin administration 
show a plasma half-tlife (t1/2) of approximately 40-60 minutes with an estimated oral 
bioavailability of 15-20%.
108, 109
  Oral melatonin undergoes extensive first past 
metabolism in the liver, with much being excreted in the urine as 6-hydroxymelatonin 
sulfate.  Distribution of exogenous melatonin into body tissues has yet to be determined.  
Timing of oral administration is important based on the intended effects of treatment.  
Burgess et al. found that administration of 3 mg oral melatonin in the early morning 
resulted in a phase delay while administration in the afternoon caused a phase advance; 
administration of melatonin around bedtime had the least phase shifting effects.
110
  
Different doses of melatonin may need to be timed differently to reduce the likelihood of 
phase shifting one‟s circadian rhythm.110  In this study, we utilized a 3 mg dose of 
melatonin.  The effects of melatonin supplementation on bone have not been 
investigated; therefore, there was no previous data to indicate the dose needed to alter 
bone physiology.  For this study, a dose was chosen that was known to produce a 
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physiological effect.  Melatonin was given at bedtime in order to minimize disruptions in 
circadian rhythm.   
Research Objective  
Melatonin supplementation has the potential to prevent the bone loss associated 
with perimenopause as well as relieve symptoms such as sleep disturbances that can 
negatively impact quality of life.  The purpose of this pilot study was to investigate the 
effects of daily nocturnal melatonin supplementation in perimenopausal women over the 
course of six months.  Bone density and bone turnover markers were measured to 
determine how melatonin effects bone health. Quality of life was also assessed through 
validated questionnaires and daily participant diaries. This study was approved by the 
Duquesne University Institutional Review Board. 
Hypothesis 
Daily nocturnal melatonin supplementation in perimenopausal women will 
prevent decreases in bone density, regulate serum markers of bone metabolism, and 
improve quality of life through regulation of sleep and improvement of menopausal 
symptoms. 
Specific Aims 
1. Assess the feasibility of recruiting perimenopausal women willing to participate 
in a blinded, randomized clinical study of melatonin versus placebo 
2. Assess the effects of melatonin versus placebo on markers of bone health and 
subject-reported outcomes of quality of life in perimenopausal women 
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METHODS 
Recruitment and Enrollment 
Several recruitment strategies were utilized including advertisements in 
neighborhood and city newspapers, posting of flyers, on-campus advertising via 
Duquesne University‟s DU Daily website, and news features in the Duquesne University 
Times and DU Alumni magazine.   Interested women were instructed to call the study 
phone number at which time a phone interview was scheduled.  During the initial phone 
screening, the expectations of the study were detailed, and the potential participant was 
asked questions to determine eligibility.  Inclusion criteria consisted of a woman being 
age 45 or older, experiencing an irregular menstrual cycle, and having had at least one 
menstrual period in the past six months.  These criteria were used to define the potential 
participant as perimenopausal.  If all inclusion criteria were satisfied, the interview 
proceeded with inquiries regarding exclusion criteria.    
Exclusion criteria were developed based on elimination of factors that may impact 
bone health, quality of life measures, or were of safety concern.  Women taking any 
medication that could potentially alter bone turnover markers were excluded.  These 
medications included hormone therapy or hormonal birth control, prescription 
medications for thinning bones (current or within past three months), and chronic use of 
steroid medications (current or within past six months) as glucocorticoid use can cause 
secondary osteoporosis.
111
  Women with a diagnosis of osteoporosis were excluded 
because we wanted to examine the effects of melatonin on bone in healthy women.  
Current smokers were excluded as smoking has been associated with decreases in bone 
mineral density
112
 and may impact bone marker status.  Hyperparathyroidism is an over 
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abundance of PTH, which can greatly alter bone turnover; therefore, women with this 
condition were excluded from participation.  Women with multiple myeloma or other 
cancers were excluded as these diseases can impact bone metabolism and may impact 
bone turnover markers, especially if the cancer metastasizes to the bone.  Other exclusion 
criteria included use of sleep medication or antidepressants due to effects on quality of 
life endpoints such as sleep quality and mood.  Women with severe sleep apnea or 
chronic obstructive pulmonary disease were not eligible to participate as these conditions 
can impact sleep quality and may influence sleep endpoints in the study.  Women with 
uncontrolled high blood pressure or those currently taking medication for blood pressure 
were excluded due to safety concerns as melatonin has antihypertensive effects.
113
  Liver 
disease was an exclusion criterion because liver impairment may interfere with the 
bioavailability of orally administered melatonin.  Women with severe lactose intolerance 
were not eligible because all study medication was compounded with lactose. 
  Those women deemed eligible to participate were asked to schedule an initial 
visit to the Center for Pharmacy Care at Duquesne University.  Potential participants 
were sent an information packet before their first visit including a welcome letter, 
directions, a map to the Center for Pharmacy Care, a brochure about bone density testing, 
an information sheet, and a copy of the informed consent form.  The information sheet 
contained answers to questions potential subject may have including what to expect at 
their visit, where to park, and how to contact the study team.  The information packet was 
provided to alleviate participant concerns about the study visit and to encourage study 
participation. Participants were given the informed consent form prior to enrollment to 
allow women adequate time to read and understand the document.    At the first 
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appointment, participants were screened for bone health using the Achilles Insight 
ultrasonometer (GE Healthcare).  Women with a T-score less than -2.0 were not enrolled 
in the study and were advised to follow-up with their primary care physician.  Three 
blood pressure readings were also taken to ensure the participant had an average blood 
pressure below 140/90 and above 100/60.  Women fulfilling the bone density and blood 
pressure requirements were asked to enroll in the study.  Informed consent was obtained 
from all study participants. This study was approved by the Duquesne University 
Institutional Review Board. 
Randomization, Blinding, Allocation Concealment, and Treatment 
Randomization: A total of 20 perimenopausal women were desired for this study.  
An initial power analysis calculated with a sample size of 10 per group, our study would 
have 80% power to detect an estimated difference in serum bone markers between groups 
of 0.89.  The sample sizes were modified after a research team meeting with all 
investigators.  As this was a pilot study and we were primarily interested in how 
melatonin induces changes over six months, the decision was made to randomize more 
individuals in the treatment group (3:1 ratio of treatment to placebo).  This distribution 
would allow us to obtain an estimate of the effect of the treatment as precisely as 
possible.  Enrolled participants were assigned to receive either placebo (n = 5) or 3 mg 
melatonin (n=15) treatment based on a computer generated randomization scheme.  The 
actual group assignment was performed using a computerized random number generator. 
Blinding: In the informed consent form, subjects were told they would be 
randomized to one of two treatment groups.  Subjects were blinded as to which treatment 
group they were assigned.  Additionally, principal and co-investigators had no knowledge 
24 
 
of group assignments throughout the study period, thus ensuring a double-blinded design.  
Investigators were unblinded after all participants had completed follow-up and analysis 
had been performed. 
Allocation Concealment: Steps taken to ensure allocation concealment consisted 
of the primary and co-investigators having no knowledge of the next treatment 
assignment for each subject.  The total time to recruit study groups was approximately 
eighteen months.  The research coordinator kept the study subject identification number 
and their group assignment in a secure location.  Only the research coordinator was 
privileged to this information as subjects entered the study.  Additionally, since the 
primary outcome was a numerical measurement obtained from a blood sample, there was 
no bias with respect to the research coordinator knowing the assignment. 
Treatment: Identical placebo and melatonin capsules (Figure 4) were formulated 
using lactose or 3 mg melatonin in lactose respectively and packaged into individual 30-
day blister packs by Avalon Pharmacy (Avalon, PA).   
 
Figure 4: Study medication in identical blister packs. 
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Compounding of capsules was necessary to keep the formulation consistent between 
placebo and melatonin capsule as well as ensures the placebo contained identical 
ingredients with the exception of melatonin. Three milligrams is the commonly available 
supplemental dose of melatonin in the United States. There is no precedence for what 
dose of melatonin is necessary for effects on bone; therefore, a 3 mg dose was selected 
because it is capable of producing a measurable physiological response as evidenced by 
phase shifts in circadian rhythm with 3 mg oral tablets.
110
  The timing of the dose was 
chosen because melatonin will not cause a significant phase shift in circadian rhythm if 
taken at a subject‟s usual bedtime.110   
Enrolled study participants were asked to commit to monthly visits to the Center 
for Pharmacy Care over a six month period for a total of seven visits (months 0, 1, 2, 
etc.).  Serum markers of bone metabolism show significant changes in approximately 3-6 
months in women taking bisphosphonates
32
 or teriparatide
33
 for osteoporosis; therefore, 
we felt six months would be a adequate time period to detect changes in markers of bone 
turnover with melatonin. During the baseline visit (month 0), subjects were asked to 
complete forms detailing basic demographic information as well as listing all regular 
prescription and non-prescription drug and/or supplement use.   Participants were given a 
one-month supply of study medication and were instructed to take one pill approximately 
two hours before bedtime.  A daily journal was also provided to collect information 
regarding compliance, sleep duration, menstrual cycling, physical activity, and any other 
information the participant deemed relevant to how she was feeling.  Participants were 
asked to bring their empty pill pack as well as their completed diary pages to the next 
study visit.  Diary pages were color-coded by month to facilitate return of completed 
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portions at each study visit. Empty blister packs were utilized to track compliance with 
taking study medication.  At each monthly visit, three blood pressure readings were 
obtained by the study nurse to ensure melatonin did not adversely impact blood pressure.  
Participants were also asked to report any adverse effects at each visit. 
Assessment of Bone Density 
Bone density was measured monthly by ultrasound of the os calcis (heel) using 
the Achilles InSight ultrasonometer (GE Healthcare, Waukesha, WI).  Participants were 
asked to place their bare foot between the ultrasound membranes. Measurements were 
taken on the non-dominant foot (e.g. measurement of the left foot in a right-hand 
dominant person) to account for possible differences in bone density that may result from 
favoring the dominant foot.  The assessment area was sprayed with ethanol to thoroughly 
wet the foot and membranes to ensure proper signal transduction. During measurement, 
the membranes filled with warm water to completely surround the subject‟s heel.  Results 
were reported as T-scores, a measure of how many standard deviations the ultrasound 
reading of the participant compares to the reading of a healthy young adult at peak bone 
mass.  A positive T-score indicates bone density above a young adult; a negative T-score 
indicates bone density less than a young adult.  Changes to bone density as measured by 
ultrasound can take up to a year or more to be detectable.   Therefore, monthly changes in 
bone density were not expected, and only the month 0 and month 6 measurements were 
used in analyses.  
Collection and Storage of Serum Samples 
Serum samples were collected bimonthly (months 0, 2, 4, and 6) during daytime 
study appointments. Participants were not required to fast.  Blood was obtained by the 
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study nurse via venous puncture using a BD Vacutainer Safety-Lok blood collection set 
with a 23 gauge needle.  Samples were collected in 8.5 ml BD Vacutainer SST Plus blood 
collection tubes.  Blood was allowed to clot for at least 30 minutes at room temperature 
before centrifugation at approximately 1200 x g for 15 minutes.  Serum was removed 
from separating gel, aliquoted, and stored at -20˚C until use. 
Assessment of Bone Turnover Markers (BTMs) 
In order to investigate changes in bone metabolism, two markers of bone turnover 
were measured in serum taken at months 0, 2, 4 and 6. Osteocalcin was measured using 
the N-MID® Osteocalcin enzyme-linked immunosorbent assay (Immunodiagnostics 
Systems, Fountain Hills, AZ) to monitor formation of new bone by osteoblasts. The 
osteoclast marker, amino-terminal cross-linking telopeptide of type I collagen (NTX), 
was used as an indicator of bone resorption.  NTX levels were determined using the 
Osteomark® NTx serum enzyme immunoassay (Inverness Medical, Princeton, NJ).  
Procedures were carried out according to the manufacturers‟ instructions.  
Osteocalcin was measured to determine how melatonin treatment affected bone 
formation.  Serum samples were pipetted into individual microplate wells precoated with 
streptavidin.  Two monoclonal human antibodies against osteocalcin – one biotinylated 
and one peroxidase conjugated – were added to each well and incubated with the sample 
for two hours. Each antibody recognizes a different amino acid portion of osteocalcin. 
Osteocalcin in the sample is captured and held to the microplate well by interaction with 
the antibodies. After a series of washes, a chromogenic agent was added to produce a 
color in the presence of antibody-bound osteocalcin.  The absorbance of each well was 
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measured to determine the concentration of osteocalcin present. Samples with more 
osteocalcin had higher absorbance values. 
NTX was measured to determine if melatonin had an impact on bone resorption. 
Serum samples were added to microplate wells containing an adsorbed NTX epitope.  A 
horseradish peroxidase conjugated monoclonal antibody was added to each well.  NTX in 
serum samples competes with the adsorbed NTX for binding sites on the antibody.  After 
incubation, a series of washes were performed to remove unbound sample and NTX in 
the sample bound to the antibody.  A chromogenic agent was added to detect the amount 
of antibody bound to NTX on the microplate well.  The absorbance of each well was 
measured to determine the concentration of NTX in each sample. A decrease in 
absorption value indicated a higher serum NTX level. 
Concentrations of osteocalcin and NTX were determined using the Perkin Elmer 
Victor
3
 1420 Multilabel plate reader with Workout 2.0 software (Waltham, MA). 
Absorbance readings of standards, controls, and subject samples were measured at 450 
nm for both the osteocalcin and NTX immunoassays. A standard curve was generated for 
each assay using the four parameter logistic curve fit function as recommended by each 
assay protocol.  Sample concentrations were calculated by Workout 2.0 software based 
on the generated standard curves. Figure 5 illustrates sample standard curves from both 
the osteocalcin and NTX immunoassay. Additional standard curves can be found in 
Appendix A. 
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Figure 5: Sample immunoassay standard curves 
Serum Melatonin Levels 
In order to determine whether baseline melatonin levels were related to treatment 
outcome, daytime serum melatonin levels were measured for each participant using blood 
samples taken at the baseline visit.  Melatonin was also measured at the end of the six-
month study to observe any changes in melatonin levels with treatment. Serum samples 
were analyzed using the melatonin direct radioimmunoassay kit (IBL International, 
Toronto, ON).  The assay was carried out according to the manufacturer‟s instructions.  
Briefly, serum samples were combined with melatonin 
125
I-Tracer and a polyclonal 
melatonin antibody.  After overnight incubation, precipitating antiserum was added and 
tubes were centrifuged to pellet the precipitate. All liquid was removed via vacuum 
aspiration.  The amount of radioactivity in each tube was assessed using the Perkin Elmer 
Packard Cobra II Auto-Gamma 5000 Series gamma counter to obtain counts per minute 
(cpm). The cpm value for non-specific binding (NSB) was subtracted from all other cpm 
values. The percentage of binding in each tube compared to the 0 pg/ml control tube (Bo) 
was calculated to obtain the (B/Bo) % value using the equation: 
 
𝐵
𝐵𝑜
 % =  
𝑐𝑝𝑚𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑐𝑝𝑚𝑁𝑆𝐵
𝑐𝑝𝑚𝐵𝑜 − 𝑐𝑝𝑚𝑁𝑆𝐵
 × 100 
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A standard curve ranging from 2.5 – 750 pg/ml was generated using a nonlinear curve fit 
algorithm for one site competitive binding assays (Figure 6, GraphPad Prism version 
5.01). Melatonin serum concentrations were determined by taking the antilog of the log 
melatonin concentration corresponding to the sample (B/Bo) % value on the standard 
curve.  Samples with levels below the limit of detection (< 2.5 pg/ml) were assigned a 
value of 2.5 pg/ml. 
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Figure 6: Melatonin RIA standard curve.  A standard curve was generated by plotting (B/Bo) % 
versus the log of the melatonin concentration for each standard.  Standard concentrations 
ranged from 2.5 pg/ml to 750 pg/ml melatonin. 
 
Menopausal Quality of Life 
Participants were asked to complete the Menopause-Specific Quality of Life – 
Intervention (MENQOL) questionnaire
114
 at both the initial and final study visits.  This 
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validated questionnaire consists of 32 menopausal symptoms divided into four domains: 
vasomotor, psychosocial, physical, and sexual.  The full questionnaire is reproduced at 
the end of the Methods section.  Subjects were asked to indicate if they experienced a 
specific symptom and, if so, to rate how bothered they were on a scale of 0 (not bothered) 
to 6 (extremely bothered).  Questionnaires were scored according to established 
guidelines to obtain scores for each of the four domains.
114, 115
   Briefly, each survey item 
was scored on scale of 1 to 8 with 1 corresponding to a “no” answer regarding the 
symptom and 8 corresponding to an answer of “yes” with the maximum “bothered 
rating” of 6. Domain scores were obtained by calculating the mean of all item scores 
within that particular domain. The vasomotor domain was composed of items 1-3.  The 
psychosocial domain included items 4-10.  Items 11-26 and 30-32 made up the physical 
domain. The sexual domain consisted of items 27-29.  Missing or incomplete data were 
handled as described.
114, 115
   If an entire item was missed on the month 0 questionnaire, 
the imputed score for that item was determined as the mean of the item score for all 
participants who responded.  This situation was encountered on one survey throughout 
the study.  If the missing item score was on the month 6 questionnaire, then the missing 
value was calculated as the mean of the item score from all participants in the subject‟s 
treatment group.  Incomplete items occurred when a “yes” was indicated but no rating 
was checked.  For this situation, the item score was determined by calculating the mean 
of the “bothered” ratings from all other “yes” answers within the domain on the subject‟s 
own survey.  Incomplete items occurred on only two surveys, one at month 0 and one at 
month 6 from two different subjects. Differences in domain scores between month 0 and 
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month 6 were calculated for each participant.  Differences in domain scores were 
compared between the placebo and melatonin treatment groups. 
Sleep Quality 
The Pittsburgh Sleep Quality Index (PSQI) survey
116
 was administered to 
participants at the month 0 and month 6 study visits to determine the effect of melatonin 
treatment on sleep.  The PSQI is a validated questionnaire used to distinguish between 
“good” and “poor” sleepers.116  Participants answered a series of questions from seven 
categories which determine overall sleep quality – subjective sleep quality, sleep latency, 
sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, 
and daytime dysfunction.  Questionnaires were scored according to published guidelines  
to obtain a global PSQI score ranging from 0 to 21, with a higher score indicating 
difficulty in multiple areas affecting sleep quality.
116
  Differences in global PSQI scores 
from month 0 to month 6 were calculated for each individual.  Mean differences were 
compared between treatment groups. 
Daily Diary 
Participants were given a daily journal to capture information about compliance, 
use of prescription and non-prescription medications, the number of hours slept each 
night, menstrual cycling, exercise, and feelings of well-being.  Journal entries were 
utilized to assess changes in menstrual cycling over the course of the study.  Each day 
women were asked to indicate if their period began or ended.  Women were excluded 
from analysis if diaries were not complete enough to determine length of period, number 
of periods, or both.  Two women were excluded from all evaluations of menstrual 
cycling. One woman was diagnosed with uterine fibroids, and the other subject had 
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sustained episodes of heavy bleeding such that cycling was not evident in diary 
information.  Journals were also used to estimate the average number of hours slept each 
month for each participant.  Missing values were estimated using mean replacement.  The 
number of nights in which sleep disturbances were recorded by each individual was also 
examined.   
Statistical Analysis 
Descriptive statistics (means, medians, standard deviations, and various frequency 
distributions) were used throughout the dissertation to describe the variables collected.   
To check the randomization was effective,  a comparisons of the baseline characteristics 
between placebo and melatonin participants was performed  using Student‟s t-test for 
independent samples (continuous data) and Fishers exact test (categorical data).  
Treatment differences in continuous variables measured at month 0 and month 6 were 
analyzed by first calculating the difference between the times for each individual and 
these individual differences were compared between treatment groups using Student‟s t-
test with Welch‟s correction. This test  is equivalent to performing a mixed models 
analysis with group (fixed effect), subject nested within group (random effect), time 
(fixed effect) and time by group interaction (fixed) terms in the model and  testing the 
group term within the model.  Similarly, continuous variables with repeated measures 
over time (0, 2, 4, and 6 months) were also analyzed using mixed effects analysis of 
variance (except time was considered random).  Means between groups at each time point 
were tested using Tukey‟s HSD post-hoc multiple comparison procedure. Statistical 
testing was carried out using GraphPad Prism version 5.01 for Windows (GraphPad 
Software, San Diego, CA) and JMP versions 8 and 9 (SAS Institute Inc, Cary, NC).  
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Results were considered significant at p < 0.05. Analysis was performed using the 
intention-to-treat principle. 
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MENQOL Questionnaire 
Reprinted from Maturitas, 50(3), Lewis JE, Hilditch JR, Wong CJ, Further psychometric 
property development of the Menopause-Specific Quality of Life questionnaire and 
development of a modified version, MENQOL-Intervention questionnaire, pp 209-221, 
Copyright 2005, with permission from Elsevier. 
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MENQOL Questionnarie continued 
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Pittsburgh Sleep Quality Index 
Reprinted from Psychiatry Research, 28(2), Buysse DJ, Reynolds CF, 3rd, Monk TH, 
Berman SR, Kupfer DJ, The Pittsburgh Sleep Quality Index: a new instrument for 
psychiatric practice and research, pp 193-213, Copyright 1989, with permission from 
Elsevier. 
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Pittsburgh Sleep Quality Index continued 
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RESULTS 
Specific Aim One  
The effectiveness of the various recruitment strategies we employed are shown in 
Table 1.   In terms of generating interest in the study, the article published in the 
Pittsburgh Tribune-Review
117
 on Monday, March 23, 2009 was the most effective; 
however, none of the women who responded to this article were ultimately enrolled in the 
study.   The low enrollment from this method of advertisement may be due to ambiguity 
in the article itself, which resulted in more postmenopausal women responding than 
perimenopausal women.  The majority of enrolled participants were recruited through 
advertisements aimed at the Duquesne University community and by word-of-mouth.    
Table 1: Effectiveness of Recruitment Strategies 
Method of Recruitment Number of 
Inquires 
Number Enrolled 
in Study 
DU Alumni Magazine article 9 3 
DU Daily 13 3 
DU Newspaper article 1 0 
Flyer 6 1 
Newspaper Advertisements 6 3 
South Hills Almanac article 5 3 
South Pittsburgh Reporter 3 0 
Tribune-Review article 20 0 
Word-of-mouth 13 6 
Other 2 0 
Unknown 19 0 
DU: Duquesne University 
 
The results of the recruitment and enrollment processes are illustrated in Figure 7.  
Of the 97 respondents, 82 (84.5%) were reached for a phone screening.  Of those 
completing the phone interview, 34% did not meet the inclusion criteria of being 
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perimenopausal and 22% were not eligible based on exclusion criteria.  The three most 
common reasons for exclusion we encountered were use of medication for depression or 
anxiety (33% of those excluded), being a current smoker (33%), and use of hormone 
replacement therapy or hormonal contraceptives (22%).  Perhaps the largest obstacle 
faced during recruitment and enrollment were the 13 women who were eligible for the 
study but for their own reasons chose not to participate. The most common reason for not 
enrolling was lack of time and not being able to commit to the monthly visits over the six 
month study period.  Information regarding the sample population utilized in this study is 
provided in Table 2.  
Table 2: Sample population characteristics 
 Mean ±  SD Range 
Age (years) 49.5 ± 3.0 45.1 – 54.5 
BMI (kg/m2) 24.6 ± 4.0 17.9 – 31.1 
Serum Melatonin (pg/ml) 26.8 ± 24.9 2.5 – 75.9 
Serum Osteocalcin 
(ng/ml) 
12.3 ± 3.9 3.8 – 18.4 
Serum NTX (nM BCE) 12.3 ± 4.1 6.1 – 19.3 
T-score (calcaneus) -0.5 ± 1.0 -1.8 – 1.6 
Vitamin Supplementation 72% (13/18) N/A 
MENQOL   
Vasomotor 2.2 ± 1.2 1.0  – 4.7 
Psychosocial 3.2 ± 1.4 1 .0 – 5.9 
Physical 2.8 ± 1.2 1.2 – 4.9 
Sexual 2.4 ± 2.2 1.0  – 8.0 
PSQI 5.1 ± 2.6 1 .0 – 11.0 
Mean ± SD; n = 18; BMI, body mass index based on patient-
reported height and weight; NTX, amino-terminal cross-
linking telopeptide of type I collagen; BCE, bone collagen 
equivalents; MENQOL, Menopause-Specific Quality of Life; 
PSQI Pittsburgh Sleep Quality Index 
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Figure 7: Flow of recruitment and enrollment. A total of 97 women responded to 
advertisements. Nineteen women were randomized, but one woman in the melatonin 
group withdrew after only two days in the study.  A total of 5 women in the placebo 
group and 13 women in the melatonin group were included in all analyses. ITT, 
intention-to-treat 
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Specific Aim Two 
Out of 97 respondents, a total of 19 women were initially enrolled in the study; 
however, one subject withdrew after two days.  The subject refused to participate in the 
study, and since no follow-up data was obtained, the principal investigator decided this 
individual would be removed and not considered part of the study.  Thus, the intention-
to-treat analysis consisted of five women in the placebo group (all with complete follow-
up) and thirteen women in the treatment group (all with complete follow-up).  All women 
self-identified as Caucasian and ranged in age from 45-54.5 years.  Baseline differences 
between groups are illustrated in Table 3.  Subjects in the melatonin group were 
significantly older compared to placebo subjects (50.3 vs 47.5, respectively).  The age 
difference may not be clinically relevant as there is no set age for the perimenopausal 
stage.  The stage of perimenopause (early versus late) may be a more important factor 
than age.  Older women may show biological differences such as more menopausal 
symptoms if they are in a later stage of perimenopausal.  As may be expected with an 
older perimenopausal population, MENQOL vasomotor domain scores, including items 
such as hot flashes, were also significantly higher at baseline in the melatonin group (2.5 
vs 1.3).  All other variables were not significantly different between groups.  
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Table 3: Baseline characteristics 
 Placebo 
(n=5) 
Melatonin 
(n=13) 
Age (years) 47.5 ± 2.0(45.4 – 50.7) 50.3 ± 3.0 (45.1 – 54.5)* 
BMI (kg/m2) 21.7 ± 3.5 (17.9 – 26.9) 25.7 ± 3.7 (18.2 – 31.1) 
Serum Melatonin (pg/ml) 41.9 ± 27.5 (2.5 – 75.9) 21.1 ± 22.3 (2.5 – 70.8) 
Serum Osteocalcin 
(ng/ml) 
14.1 ± 3.9 (9.5 – 18.4) 11.6 ± 3.8 (3.8 – 17.6) 
Serum NTX (nM BCE) 12.0 ± 4.4 (6.1 – 16.4) 12.4 ± 4.2 (7.3 – 19.3) 
T-score (calcaneus) -0.8 ± 0.8 (-1.8 – 0.1) -0.4 ± 1.1 (-1.5 – 1.6) 
Vitamin Supplementation 80% (4/5) 69% (9/13) 
MENQOL   
Vasomotor 1.3 ± 0.8 (1.0 – 2.7) 2.5 ± 1.3 (1.0 – 4.7)* 
Psychosocial 2.9 ± 0.8 (1.9 – 3.9) 3.3 ± 1.6 (1.0 – 5.9) 
Physical 2.0 ± 0.9 (1.3 – 3.6) 3.1 ± 1.2 (1.2 – 4.9) 
Sexual 2.0 ± 1.4 (1.0 – 4.3) 2.6 ± 2.4 (1.0 – 8.0) 
PSQI 5.0 ± 1.0 (4.0 – 6.0) 5.2 ± 3.0 (1.0 – 11.0) 
Mean ± SD (Range); BMI, body mass index based on patient-reported height and weight; 
BCE, bone collagen equivalents; MENQOL, Menopause-Specific Quality of Life; PSQI 
Pittsburgh Sleep Quality Index;  * p < 0.05, t-test with Welch’s correction 
 
 
Over the course of the six month study period, bone health was monitored using two 
different methods.  Changes in bone density were measured monthly at the calcaneus 
using the Achilles InSight ultrasound machine (Figure 8).  Participants in the placebo 
group had an average T-score change of -0.02 over six months.  Women in the melatonin 
group had an average change of 0.05.  A more positive T-score indicates an improvement 
in bone density.  Melatonin treatment had no significant effect on changes in bone 
density over the 6 month study period.  Appreciable changes in bone density are often not 
seen until completion of one to two years of treatment; therefore, it would be expected 
that any effect of melatonin on BMD may not be observable at this early time point. Bone 
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mineral density T-scores for each individual over the study period can be found in 
Appendix B.   
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Figure 8: Bone mineral density changes over six month study. Mean ± SEM; Change 
from baseline calculated for each individual. Mean changes between placebo and 
melatonin compared using t-test with Welch’s correction, p < 0.05; n = 5 placebo, n = 13 
melatonin.  
 
In addition to bone density, markers of bone metabolism were measured in serum 
samples collected bimonthly (months 0, 2, 4, and 6) via venous puncture.  The osteoclast 
marker, amino-terminal cross-linking telopeptide of type I collagen (NTX), was used as 
an indicator of bone breakdown.  Osteocalcin was measured to monitor formation of new 
bone by osteoblasts.  Both of these markers have been measured in perimenopausal 
women.
8, 9, 14, 35
   Additionally, they were stable enough to be stored for assay at a later 
date; due to our rolling recruitment, samples were not always run immediately but were 
frozen until enough samples were collected to complete a full immunoassay plate. 
Changes in bone turnover markers in response to bisphosphonates can be seen as early as 
three months
32
; therefore, these markers may provide information about the effect of 
melatonin on bone at an earlier time than ultrasound. Figure 9 illustrates the changes in 
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bone turnover markers for both placebo and melatonin treatment groups. No significant 
treatment effects were found over time using mixed models analyses for either 
osteocalcin or NTX.  Graphs illustrating the changes in bone markers for each participant 
can be found in Appendix B. 
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Figure 9: Serum osteocalcin and NTX levels over six month study period. (A) serum 
osteocalcin (B) serum NTX. n = 5 placebo, n = 13 melatonin. Data expressed as mean ± SEM.  
At all time points, differences between treatment groups were non-significant for each bone 
marker as determined by mixed model analyses. 
 
 The remodeling and maintenance of bone is a tightly coupled process that requires 
a balance in osteoclast and osteoblast activities such that breakdown of old bone is 
coupled with formation of new bone.  Current therapies, with the exception of the 
anabolic agent teriparatide, work by inhibiting osteoclasts to slow breakdown of bone.
22, 
27
  Melatonin is unlike standard osteoporosis therapies in that it has the potential to both 
stimulate osteoblasts
46, 60
 as well as inhibit osteoclast activity.
63
  Due to its unique action 
on bone, we wanted to examine the coupling between osteoclast and osteoblast activity in 
each treatment group.  Figure 10 illustrates the changes in osteocalcin and NTX levels 
over time for the placebo (panel A) and melatonin (panel B) treatment groups.  Panel C 
of Figure 10 shows how the ratio of osteoclast activity to osteoblast activity (expressed at 
67 
 
the ratio of NTX to osteocalcin levels) changes over the study period.  Ratios in the 
melatonin group appear to be trending towards one over time, possibly indicating a more 
even balance between osteoclast and osteoblast activity as seen in premenopausal 
women.  Also interesting to note is the slight increase in osteocalcin from month 0 to 
month 2 with melatonin treatment that continued throughout the duration of the study. 
Also interesting is the slight downward trend of NTX after the two-month timepoint.  
This pattern is not seen in the placebo group.  Thought it is difficult to draw conclusions 
based on the small sample size, it is possible that melatonin may induce an increase in 
osteoblast activity, improving bone marker status in perimenopausal women.  This idea is 
also supported by Figure 10C which reveals a time-dependent trend towards an NTX:OC 
ratio of 1:1 in the melatonin treatment group.  Future studies should examine multiple 
markers of osteoblast activity such as bone-specific alkaline phosphatase to determine if 
the same pattern occurs in a larger population and with additional bone markers.
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Figure 10: Ratio of bone turnover markers by treatment group. (A) Osteocalcin (left axis) and 
NTX (right axis) levels for placebo group (n = 5) (B) Osteocalcin (left axis) and NTX (right axis) 
levels for melatonin group (n = 13). Data expressed as mean ± SEM. (C) Ratio of osteoclast to 
osteoblast activity calculated as the ratio of NTX to osteocalcin serum levels. Bars within each 
month indicate mean.  
  
Daytime serum melatonin levels were assessed at month 0 to determine if 
endogenous melatonin levels predicted a response to melatonin treatment as one previous 
study found a relationship between endogenous melatonin peak levels and response to 
exogenous supplementation for sleep.
118
  Month 6 melatonin levels were measured to 
detect changes in melatonin levels after treatment.  Figure 11 shows the raw data for the 
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measurement of daytime serum melatonin levels.  Several samples, particularly in the 
melatonin treatment group, were below the limit of detection. Values varied widely at 
both months 0 and 6, ranging from undetectable to 75 pg/ml.    When undetectable 
samples were assigned a value of 2.5 pg/ml (the limit of detection), the mean (± standard 
deviation) baseline serum melatonin levels for the placebo and melatonin groups were 
41.9 ± 27.5 pg/ml and 21.1 ± 22.3 pg/ml, respectively.  Median values at baseline were 
49.0 pg/ml in the placebo group and 13.2 pg/ml in the melatonin group.  After the six 
month study period, mean values were 37.1 ± 23.0 pg/ml in the placebo group and 20.1 ± 
26.6 pg/ml in the melatonin group.  Median values for placebo and melatonin groups at 
month 6 were 43.7 pg/ml and 2.5 pg/ml, respectively. There is variability in what value to 
assign samples with levels below the limit of detection.  Options could include assigning 
a value of zero, using the limit of detection measure, or choosing the value midway 
between.  Due to the number of undetectable samples, it may be inappropriate to perform 
statistical analysis.  Looking at the data by individual person (Appendix B), six subjects 
in the melatonin group had serum levels below the limit of detection at both baseline and 
month 6 time points.  Of the five remaining subjects in the melatonin group, three had 
values decrease between baseline and month 6 follow-up while two subjects had an 
increase from baseline to month 6.  Overall, it does not appear that melatonin treatment 
had an effect on daytime serum melatonin levels.  Baseline daytime melatonin levels did 
not appear to predict the degree of bone marker changes; however, daytime melatonin 
levels may not reflect the peak level of melatonin secreted at nighttime.  A 24-hour 
melatonin profile would be necessary to fully assess a relationship between melatonin 
levels and degree of response to treatment.   
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Figure 11: Daytime serum melatonin levels.  Serum melatonin levels were determined at 
months 0 (baseline) and 6 by radioimmunoassay.  Several samples had levels below the limit 
of detection (< 2.5 pg/ml) and are indicated by the  symbol. 
 
 The MENQOL-Intervention survey was administered at month 0 and month 6 to 
determine the impact of melatonin supplementation on menopausal symptoms. 
MENQOL vasomotor, psychosocial, and sexual domain scores did not change 
significantly with melatonin treatment; however, participants taking melatonin had 
significant improvement in their MENQOL physical domain scores (Table 4) compared 
to those in the placebo group (-0.6 vs 0.1, respectively). The decrease in MENQOL 
physical domain score indicates an improvement in physical symptoms with melatonin 
treatment. Items included in the physical domain included feeling tired or worn out, 
difficulty sleeping, breast pain, and vaginal bleeding or spotting.   
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Table 4: Change in MENQOL and PSQI scores after treatment with melatonin or placebo 
 Placebo 
n = 5 
 Melatonin 
n = 13 
 Baseline Month 6 Change  Baseline Month 6 Change 
MENQOL        
Vasomotor 1.3 1.1 -0.2 (0.4)  2.5 2.9 +0.4 (1.8) 
Psychosocial 2.9 2.7 -0.2 (1.3)  3.3 2.9 -0.4 (1.3) 
Physical 2.0 2.1 +0.1 (0.5)  3.1 2.5 -0.6 (0.8)* 
Sexual 2.0 1.3 -0.7 (1.4)  2.6 2.2 -0.4 (1.2) 
PSQI 5.0 4.0 -1.0 (1.4)  5.2 4.7 -0.5 (2.8) 
Mean (SD); MENQOL, Menopause-Specific Quality of Life; PSQI Pittsburgh Sleep Quality 
Index; * p < 0.05, t-test with Welch’s correction 
 
Information in participant diaries was examined to continue exploring the effect of 
melatonin on physical aspects of the menopausal transition.  Menstrual cycle patterns 
over the six month study period were charted based on information reported in daily 
diaries. Women were excluded from analysis if diaries were not complete enough to 
determine duration of period, number of periods, or both.  Two women were excluded 
from all evaluations of menstrual cycling. One woman was diagnosed with uterine 
fibroids, and the other subject had sustained episodes of heavy bleeding such that cycling 
was not evident in diary information. Women in the melatonin group reported 
significantly fewer periods during the six month study (Figure 12A) compared to those 
subjects in the placebo group (4.3 ± 0.6, n = 10 melatonin vs 6.5 ± 0.3, n =4 placebo; 
mean ± SEM) and a correspondingly higher number of days between periods (Figure 
12B; 51.2 ± 11.4, n = 10 melatonin; 24.1 ± 0.9, n = 4 placebo), suggesting melatonin may 
influence menstrual bleeding patterns in perimenopausal women.  Average duration of 
menstrual periods was not different between treatment groups (Figure 12C).   
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Figure 12: Menstrual cycling differences between treatment groups. Based on menstrual 
cycles recorded in subject diaries, subjects receiving melatonin reported significantly fewer 
periods (A; 4.3 ± 0.6, n = 10 melatonin vs 6.5 ± 0.3, n =4 placebo; mean ± SEM; p < 0.05) 
and a greater number of days between periods (B; 51.2 ± 11.4, n = 10 melatonin; 24.1 ± 
0.9, n = 4 placebo; p < 0.05).  There was no significant difference in the average length of 
periods between treatment groups (C; 5.9 ± 0.5, n = 9 melatonin; 6.7 ± 0.8, n = 3 placebo; p 
> 0.05). 
 
 The PSQI survey was administered to participants to assess the impact of 
melatonin treatment on sleep quality.  The results of the PSQI survey did not capture a 
relationship between melatonin administration and improvement in overall sleep quality 
(Table 4).  As part of the daily diaries, participants were also asked to record the number 
of hours of sleep they received each night.  Analysis of participant diaries showed no 
significant impact on nightly duration of sleep (Figure 13); however, there appeared to be 
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less variability in the melatonin group.  This could be due to the higher number of 
participants in the melatonin group, or melatonin may be regulating their sleep-wake 
patterns.  Several subjects also recorded incidents of nighttime disturbances or 
interruptions; one subject in the melatonin group kept extremely detailed records about 
nighttime disturbances (Figure 13B).  Recording sleep interruptions, however, was not a 
specific entry requested in the daily journal.  Therefore, we were unable to determine 
treatment effects on sleep disturbances because not all participants provided this 
information.  
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Figure 13: The impact of melatonin on sleep patterns. A. The number of hours slept each night 
was recorded in subject diaries.  Analysis using mixed model analysis of variance showed no 
significant changes with melatonin treatment (p > 0.05); n = 5 placebo; n = 13 melatonin. B. 
Example of participant tracking the number of nighttime interruptions. Melatonin appears to 
decrease disturbances over the study period. 
Although there was no significant difference in PSQI scores with melatonin 
treatment, many participants reported stated they were sleeping better indicating an 
improvement in sleep quality.  In fact, 61.5% (8 out of 13) of subjects given melatonin 
were able to correctly identify their treatment group. When asked why they thought they 
were given melatonin, subjects reported reasons such as feeling better and sleeping better. 
Only 15% of melatonin subjects (2 out of 13) incorrectly identified the treatment group.  
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For those in the placebo group, 60% of subjects (3 out of 5) correctly identified their 
treatment group based on no change in sleep or relief of menopausal symptoms and 20% 
(1 out of 5) incorrectly identified their treatment group; the remaining placebo subject 
was undecided.  These results suggest melatonin may be improving some aspect of well-
being that could include more regular sleep patterns or improved quality of sleep; 
however, a larger trial that analyzes specific aspects of sleep quality would be necessary. 
 Blood pressure was assessed at each monthly visit to detect alterations in blood 
pressure with treatment.  The average of three measurements was recorded.  As seen in 
Table 5 and Figure 14, there appears to be a downward trend in blood pressure readings 
in both the placebo and melatonin group, possibly indicating more comfort with the study 
procedures as time progressed.  Interesting to note is the change in systolic pressure with 
melatonin treatment (Table 5; Figure 14B) which appears to show an even greater 
decrease than with placebo treatment.  Treatment with melatonin does not negatively 
impact blood pressure in our study samples and, in fact, appears to lower blood pressure.  
Individual blood pressure changes at each month can be found in Appendix B. 
Table 5: Changes in blood pressure after treatment with melatonin or placebo 
 Placebo 
n = 5 
 Melatonin 
n = 13 
 Baseline Month 6 Change  Baseline Month 6 Change 
Systolic Pressure   
(mmHg) 
118.0 115.0 -3.0 (7.8)  117.3 111.3 -6.0 (12.7) 
Diastolic Pressure 
(mmHg) 
76.4 70.6 -5.8 (5.3)  75.5 70.0 -5.5 (6.1) 
Pulse Pressure 
(mmHg) 
41.6 44.4 2.8 (5.0)  41.8 41.3 -0.5 (10.3) 
Mean (SD); No significant differences between groups found using t-test with Welch’s 
correction 
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Figure 14: Blood pressure readings after study period.  The mean of three blood pressure 
measurements is displayed for each participant at baseline and after six months.   There was an 
overall decrease in both diastolic and systolic pressure over the study period in both treatment 
groups.  The decrease in systolic pressure appears to be more dramatic with melatonin 
treatment. 
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DISCUSSION 
The first aim of this study was to assess the feasibility of recruiting 
perimenopausal women willing to participate in a clinical trial of melatonin versus 
placebo.  An important part of this pilot study was to identify the best strategies for 
maximizing interest and subject retention.  The recruitment process began in August of 
2008 and continued through January of 2010. We successfully enrolled 19 women into 
the study out of a total of 97 interested women.  Most enrolled participants were recruited 
through Duquesne University advertisements, possibly because women were more 
willing to enroll in a study at an institution with which they were associated.  Word-of-
mouth was also an effective strategy in enrolling participants.  Perhaps, a personal 
account of what the study is about and what enrollment entails made more eligible 
women express an interest.  Flyers and newspaper advertisements were limited in the 
amount of information that could be included.  We relied on interested women to call us 
for more details.  Recruitment avenues that allowed us to express the rationale and aims 
for the study were the most effective at generating inquiries about participation. These 
strategies included detailed articles in a local neighborhood newspaper (South Hills 
Almanac), the Duquesne University alumni magazine, and the Pittsburgh Tribune-
Review. The Tribune-Review article generated the most phone calls about participation; 
however, many women were not eligible because they were not perimenopausal.  
Inclusion and exclusion criteria can negatively impact study enrollment rates even 
though they are necessary to obtain a specific cohort of study participants. In an article by 
Panjari et al. 2008, they describe difficulty in recruiting postmenopausal women in 
Australia willing to participate in a randomized, double-blind, placebo-controlled trail of 
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oral DHEA.
119
    Panjari et al. found many women did not qualify as postmenopausal and 
were therefore not eligible to participate in their study.
119
  Many of the ineligible women 
in our study did not meet the inclusion criteria for being in perimenopause (34%) despite 
the three criteria being stated in our advertisements.  Thus, one may speculate the 
ambiguity faced clinically in describing various states during the transition through 
menopause extends to the lay population as well. Women may not understand the subtle 
differences in the terms perimenopause and postmenopause.  Many women who did not 
meet our inclusion criteria were already postmenopausal and expressed concerns about 
being at risk for osteoporosis. The majority of these women heard about our study 
through an article written in the Pittsburgh Tribune-Review
117
.  The article discussed 
postmenopausal osteoporosis, which may have led primarily postmenopausal women to 
express an interest in participation.  Perimenopausal women may have thought they were 
not through menopause and therefore did not need to or were not eligible to participate in 
the study. Women may associate osteoporosis and bone health with menopause, not 
realizing bone loss begins to occur before they have their last menstrual period.  
Indeed, lack of participation in a prevention trial can become an issue as healthy 
subjects often feel they are not in need of a therapy.
120
  Analysis of trials examining 
effective recruitment strategies have demonstrated that increased education about the 
intervention and disease state can increase recruitment in randomized trials.
121
 To 
increase recruitment in future studies surrounding bone loss during perimenopause, 
educational information about when bone loss occurs in the aging process could be 
beneficial. Also, women need to be aware they could be experiencing bone loss without 
having symptoms. In this study, eligible women were given a pamphlet in the 
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information packet with facts about osteoporosis risk, prevention, and how bone density 
is measured by ultrasound.  An additional strategy could be the use of a questionnaire 
with recruitment materials. Kendrick et al. found that the inclusion of a home safety 
questionnaire in recruitment mailings increased enrollment in an injury prevention trial 
compared to mailings without a questionnaire.
122
 Future recruitment materials for a study 
of melatonin and bone health could include a questionnaire designed to educate women 
on their risk for osteoporosis.  
Enrollment difficulties can stem from a variety of situations. In their recruitment 
of postmenopausal women, Panjari et al. found approximately 55% of women who were 
eligible after a phone screening declined to attend their first study visit.  The two most 
common reasons for non-participation were the time constraints involved with 
participation and wariness of adverse effects.
119
  In our study, 36% (13 of 36) of eligible 
women chose not to attend their initial appointment.  As with Panjari et al.
119
, we found 
women were unable or unwilling to make the time commitment or were fearful of 
possible side effects with melatonin administration.  The time constraints of work and 
family obligations may have been factors in the 36% of women who declined to 
participate in our study.  Most of the women we enrolled were working full-time.  Many 
women expressed a need for weekend hours if they were going to commit to participate 
in the study.  Offering Saturday morning hours once a month was a crucial part of our 
successful recruitment and retention of participants.  
Apprehension over taking an unknown treatment (placebo or study medication) 
can lead some people to decline enrollment in a randomized study.
120, 123, 124
  Interviews 
with people who declined participation in a randomized, placebo-controlled study of 
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aspirin revealed concerns from one individual about taking a placebo as they were 
unclear about what was in the placebo. Another person expressed concerns about not 
being given aspirin when eligibility screenings identified them as a candidate for therapy.  
In fact, some potential participants opted to go on aspirin therapy themselves without 
enrolling to ensure they were on therapy and not placebo.
120
 During the recruitment 
process for our study, one woman asked if she could be placed in the placebo group and 
subsequently declined participation because she did not want to be randomized. An 
„open‟ trial design in which subjects are aware of their treatment has been suggested as 
one method to increase recruitment
123, 124
; however, the disadvantages to having an 
unblinded trial may outweigh the increase in enrollment. Potential study participants also 
have concerns about adverse effects from treatment.  Educational material about the 
intervention may be an additional strategy to prevent eligible subjects from declining 
participation.  One woman declined to participate after reading material on a website that 
claimed melatonin could cause sleepwalking. Two other women expressed concerns 
about daytime drowsiness as listed in the potential side effects section of the study 
consent form.  We tried to address concerns potential participants may have had about 
participating in the study by mailing them an informational packet before their first 
appointment.  We hoped to make the process as simple as possible by providing 
directions, phone numbers, and a summary of what the appointment would entail.  The 
informed consent form was also provided prior to the first appointment to ensure 
potential subjects had adequate time to carefully read over the risks and benefits of 
participation and come to the appointment with any questions or concerns.  Willingness 
on behalf of the research staff to discuss any concerns may alleviate apprehension about 
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treatment; however, some people may still not feel comfortable taking an unknown 
treatment with risks of adverse effects.  Several studies have found monetary 
incentives
121, 123
 and telephone calls
123, 124
 to be effective strategies for increasing 
enrollment and retention of study participants.  We utilized both of these strategies and 
found we were successful in retaining all but one study participant who dropped out very 
early in the study.  Participants were also compensated ten dollars for each visit and 
offered parking validation.  Subjects completing the study received an additional fifteen 
dollars.  Compensation was to make up for the travel expenses associated with each 
monthly visit. All participants were called within one week of their appointments as a 
reminder; appointments were rescheduled if necessary. Participants were also given 
appointment reminder cards at their previous visit with the date and time of their next 
appointment.  We had one instance where a participant did not attend her monthly 
appointment, despite several phone calls. We were able to reach her within a week and 
have her come in for her appointment. The high retention rate and low number of missed 
appointments illustrate our ability to enroll and retain study participants utilizing these 
strategies. 
Future studies with a larger sample size may need to employ additional marketing 
strategies to increase enrollment and decrease the recruitment time period.  Through this 
study, we have identified that the most effective advertisements are those in which more 
details about the study can be given, including the purpose of the study and the benefits 
of the intervention. Future strategies targeting perimenopausal women could include 
presentations to local women‟s groups about osteoporosis, articles about the study in 
local neighborhood newspapers, and more detailed advertisements in city-wide 
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newspapers.  Educational information about osteoporosis risk may draw more interest in 
study participation, particularly for women who may not think they need to worry about 
bone health until they are postmenopausal.  Information about melatonin should also be 
included to help alleviate fears about adverse effects.  All women in enrolled in our study 
self-identified as Caucasian.  We did not collect information on race from all screened 
individuals; therefore, we cannot determine if our recruitment strategies successfully 
attracted a diverse population.  Nevertheless, efforts should be made in future studies to 
enroll a more racial and ethnically diverse population.  Strategies to increase diversity 
could include advertisements at churches and community centers in areas with high 
minority populations.  Additional studies should utilize telephone reminders, 
compensation for travel expenses, and weekend appointment hours as we found these 
strategies to be successful in recruitment, enrollment, and retention.  
The second aim of this study was to evaluate the effects of melatonin on bone 
health and quality of life.  The primary endpoints were measurements of bone health 
including assessment of bone density by quantitative ultrasonography and measurement 
of bone turnover markers (BTMs) in serum.  Quantitative ultrasound results revealed no 
significant changes in bone mineral density (BMD) after the six-month study period in 
either the placebo or melatonin treatment groups (Figure 8). Ultrasound of peripheral 
sites, such as the calcaneus, are similar to DXA scan measurements for the ability to 
discriminate between women with and without a history of hip fracture
125
 and 
osteoporotic vertebral fractures.
126
  However, DXA is still the gold standard method for 
diagnosing osteoporosis.  Peripheral BMD measurements can be obtained at the heel, 
wrist, or finger and have several benefits over DXA including reduced expense, 
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portability of the machine, and no exposure to radiation.  Bone density measurements at 
peripheral sites are often utilized for screening purposes to identify people for which 
further examination by DXA are warranted.  Although we did not see a significant 
change in T-score, this was not an unexpected result.  Changes in bone density can take a 
year or more to be observed based on the sensitivity of imaging methods. Bone density 
measurements provide information about the mass of bone but do not provide 
information about the bone microarchitecture or the rate of bone remodeling. The rate at 
which bone is being remodeled is important when considering osteoporosis as part of the 
disease pathology centers around an imbalance in bone metabolism.
11
  One way to assess 
bone remodeling is to measure biochemical markers of bone turnover.  Bone turnover 
markers can be measured in serum or urine to provide information about the bone 
metabolism on a molecular level.  BTMs are also useful for monitoring how the body is 
responding to a particular therapy.  
In this study, we utilized two markers of bone turnover: osteocalcin to monitor 
bone formation and NTX to examine bone resorption or breakdown.  As illustrated in 
Figure 9, we found no significant changes in OC or NTX over the study period in either 
treatment group. BTM expression did not differ between treatment groups at any time 
point.  In Figure 9, osteocalcin appears to increase from baseline to month 2 with 
melatonin treatment.  While not significant, this could be an indication of melatonin 
stimulating osteoblast activity.  With the sample sizes in this study, a difference of 3.2 
ng/ml would be necessary to achieve a statistically significant result as determined by 
mixed model analysis.   A sample size of 35 per group would provide enough participants 
to detect a 3.2 ng/ml change in osteocalcin with 90% power at an alpha of 0.05.  A larger 
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sample size will provide a better understanding of the ability of melatonin to alter BTM 
levels in perimenopausal women.  Although there were no significant changes in BTMs, 
there was a downward trend in the ratio of NTX to OC with melatonin treatment (Figure 
10C).  The action of bone-resorbing osteoclasts and bone-forming osteoblasts are tightly 
coupled.  Osteoporosis is be caused by a disruption in the balance of bone metabolism 
such that the action of osteoclasts outpaces osteoblasts, leading to a net loss of bone.
11
  
The ratio of a bone resorption marker to bone formation marker could provide 
information about the coupling between osteoclast and osteoblast activity.  We examined 
the ratio of NTX to OC and found a trend toward a ratio of 1.0 in the melatonin group. 
Although the individual BTMs measured were not different between treatment group, the 
downward trend in NTX:OC ratio with treatment indicates melatonin may possibly work 
to balance the activity of osteoclasts and osteoblasts.   
Serum melatonin levels were measured at baseline to determine if they could 
predict a response to treatment.  In a study of the effects of melatonin on sleep and 
activity in subjects with brain disorders, Laakso et al. found subjects with lower 
endogenous nighttime melatonin peak levels had a stronger response to treatment with 
exogenous melatonin.
118
   In our study, we did not see a vast difference in response to 
supplementation in those with high versus low daytime melatonin levels.  For example, a 
participant with undetectable daytime melatonin levels had smaller changes in BTMs (ID 
017, Appendix B) than a woman with higher daytime melatonin (ID 019, Appendix B).  
Endogenous melatonin levels may indeed be a factor in how a person responds to 
treatment; however, peak nighttime levels may be the best indicator of low versus high 
melatonin secretors.  Daytime levels may not be reflective of the peak night levels.  
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Future studies should consider collecting an initial 24-hour salivary melatonin profile in 
which participants collect saliva samples every 2-4 hours for one day.  This information 
may provide more details into the relationship between endogenous melatonin profiles 
and responses to exogenous supplementation. 
The pattern of change in BTM can depend on the mechanism of action of a 
specific treatment.  For example, antiresorptive therapies like bisphosphonates 
significantly reduce bone resorption markers early in the treatment period while bone 
formation markers do not decrease until approximately four weeks later.
34
  As 
bisphosphonates act through inhibition of osteoclast action, the early response is a drop in 
bone resorption markers.  The bone formation markers do not decline until there is an 
overall decrease in bone remodeling due to the decline in osteoclast activity.  BTM 
changes with anabolic therapy reflect a different pattern.  After treatment with 
teriparatide, bone formation markers significantly increase.  Bone resorption markers do 
not rise significantly above baseline until approximately six months after beginning 
treatment.
34
  The main mechanism of action for each of these therapies determines 
whether there will be an overall decrease (antiresorptive mechanism) or increase 
(anabolic mechanism) in both osteoblast and osteoclast markers, reflecting the overall 
effect of therapy on the bone remodeling process. Melatonin has several possible 
mechanisms of action on bone including antiresorptive and anabolic actions (Figure 15).  
As there is no currently available therapy with both antiresorptive and anabolic 
mechanisms of action, the pattern of BTM changes with this type of treatment is not 
established.  One would speculate that there may be an initial drop in resorption makers 
due to antiresorptive effects and a rise in formation markers due to anabolic effects, 
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reflecting the unique mechanisms of action with melatonin.  However, if the primary 
mechanism of action is an anabolic effect through enhancement of osteoblast activity, 
there may be an initial increase in bone formation markers followed by an increase in 
resorption markers at later timepoints, indicating an overall increase in bone remodeling.   
There are no published profiles of BTM changes with melatonin treatment in 
perimenopausal women.  Our study provides a framework illustrating how two markers 
of bone remodeling, OC and NTX, respond to melatonin supplementation. A future study 
should be conducted to investigate a panel of bone markers to determine the most 
responsive markers to melatonin treatment.   
 
Figure 15: Potential mechanisms of melatonin action on bone. Melatonin has several potential 
mechanisms through which bone changes can occur including: (a) stimulation of osteoblast 
differentiation through MT2 receptors
46, 60; (b,c) increased secretion of OPG from osteoblasts 
thereby reducing RANKL binding to RANK receptors63;  and (d) neutralization of free radicals 
produced by osteoclasts for bone resorption52. Figure Copyright © 2011 From Melatonin in the 
Promotion of Health, 2nd edition by RR Watson. Reproduced by permission of Taylor and Francis 
Group, LLC, a division of Informa plc.  
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Currently, there are no standard guidelines regarding the use of bone turnover 
markers in clinical practice or research.  As such, there are no reference standards for 
bone turnover marker values.  Recently, the International Osteoporosis Foundation and 
the International Federation of Clinical Chemistry and Laboratory Medicine (IOF/IFCC) 
highlighted the need for reference standards with regards to which bone turnover markers 
to measure in clinical studies in order to facilitate comparison of results between 
studies.
34
  They have recommended the use of procollagen type I N propeptide (PINP) as 
a marker of bone formation and carboxy-terminal cross-linking telopeptide of type I 
collagen (CTX) as a marker of bone resorption based on criteria such as known 
characteristics of each marker, availability of assay procedures, and requirements for 
handling and stability.  Perhaps consistency in the use of BTMs in clinical studies will 
facilitate the development of clinical guidelines for collection, measurement, and 
interpretation of marker changes with treatment. 
It is difficult to determine if there is an established pattern of bone turnover 
marker changes in perimenopausal women.  Firstly, there are few prospective, 
longitudinal studies examining how BTMs change over time in this population. 
Additionally, the criteria used to classify a cohort as perimenopausal differs among 
studies.  Lastly, the specific biochemical markers studied and the methods of detection 
vary widely.  One prospective, longitudinal study by Hoshino et al.
127
 found an increase 
in serum osteocalcin (bone formation), urinary deoxypyridinoline (DPD, bone 
resorption), and urinary pyridinoline (PYD, bone resorption) in perimenopausal women; 
however, measurements were only taken at baseline and after four years.  The changes in 
BTMs in the interim would have aided in establishing a possible pattern of BTM changes 
87 
 
in perimenopausal women.  Also, the perimenopausal group was defined in retrospect as 
women who began the study in premenopause and completed the study in 
postmenopause.
127
  The length of time each of the women was in the perimenopausal 
stage could influence how BTMs changed within the four year study period.  A second 
longitudinal study of bone metabolism during the menopausal transition measured three 
markers of bone resorption (PYD, DPD, and NTX in urine) and two markers of bone 
formation [plasma OC and serum bone alkaline phosphatase (BAP)] four times in a one 
year period.
35
  Seifert-Klauss et al.
35
 found significant increases in OC, PYD, and DPD 
after twelve months in the perimenopausal group.  NTX levels did not change over time 
in this group but where significantly higher overall compared to premenopausal women.  
The authors acknowledge their study may include some women who were 'late' 
premenopausal at the beginning of the study in their perimenopausal cohort based on 
their classification criteria.
35
  A similar longitudinal study published by Rosenbrock et al. 
in 2002
9
 attempted to illustrate the changes in BTMs over the course of two years. 
Several markers of bone turnover were measured at 0, 3, 6, 12, and 24 months in 
premenopausal, perimenopausal, and postmenopausal women.  As with Seifert-Klauss et 
al.
35
, this study may have included some women who were 'late' premenopausal at the 
beginning of the study in their perimenopausal cohort.  Over the course of the two-year 
study, two out of five markers of bone resorption (PYD and DPD) increased over time in 
the 19 perimenopausal women studied. Only one of the three bone formation markers 
(OC) increased in perimenopausal women over the course of two years.
9
  This study is 
perhaps the best illustration of how we would have expected the placebo group to 
respond in our study.  The placebo cohort showed no significant change in bone turnover 
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over the six month study. Rosenbrock found significant changes over a two year time 
period
9
 indicating the need for a longer study period in order to detect changes in 
untreated women over time. We only followed the change in two bone turnover markers 
for six months.  It may take a longer treatment period to fully understand the impact of 
melatonin on BTMs.   
Markers of bone turnover can be utilized in clinical research to make inferences 
about specific populations, but large biological variability has been an obstacle for 
moving analysis of BTMs into clinical practice.
128
  The lack of significant differences 
between the placebo and melatonin treatment groups may be a reflection of the variability 
between individuals, which is more evident in a pilot study with small sample sizes.  
Future studies investigating bone turnover marker changes in perimenopausal women 
should focus on minimizing sources of variation.  Controllable sources of variation in 
BTM include diet and timing of sample collection.
34, 129
  In the current study, participants 
were not required to fast.  Depending on the markers investigated, fasting may be an 
important factor.  For instance, serum CTX levels are known to decrease by 20% after 
breakfast.
129
  BTM levels can also vary depending on the timing of sample collection; 
this is particularly true for bone resorption markers as the lowest values occur in the 
afternoon and evening.
129
  In the current study, the majority of samples were taken in the 
morning; however, some participants required afternoon appointments resulting in a later 
blood collection time.  Efforts should be made in future studies to standardize the blood 
collection time, preferably in the morning. Menopausal status is also a source of variance 
when measuring BTMs.  Bone turnover markers are known to increase from 
premenopause to postmenopause.
34, 35, 129
 Perimenopausal women present a unique 
89 
 
challenge in that erratic endocrine changes characterize the perimenopausal state, which 
could possibly influence bone marker expression.  
Two cohort studies have compared BTMs between premenopausal and 
perimenopausal women.  A cross-sectional cohort study of women in Australia measured 
several markers of bone resorption and bone formation in premenopausal, 
perimenopausal, and postmenopausal women.
8
  Out of four bone resorption markers, only 
one (urinary NTX) was significantly higher in perimenopausal women as compared to 
premenopausal women. None of the three bone formation markers were different in 
perimenopausal women as compared to those in premenopause.  Interestingly, the authors 
found a significant correlation with FSH levels and several, but not all, measured markers 
of bone turnover such that high levels of FSH were correlated with increased BTMs.
8
  A 
second cross-sectional study analyzed serum osteocalcin and urine NTX levels in pre- 
and early perimenopausal women from the SWAN study.
14
 No significant differences in 
either bone marker between the two cohorts was found; however, in accordance with 
Ebeling et al.
8
, a significant positive correlation was found between FSH and BTM 
levels.
14
 FSH has been proposed to have a possible role in regulation of bone metabolism, 
possibly through activation of FSH receptors on osteoclasts to stimulate bone 
resorption.
15
  FSH levels increase as women transition through perimenopause into 
menopause. Our sample population consisted of women in both early and late 
perimenopause who most likely had a wide range of FSH values. The heterogeneity in 
FSH levels may contribute to the variability in BTMs between individuals.  The 
variability in FSH levels may be reflective of the type of menstrual cycle occurring in 
each woman.  Anovulatory menstrual cycles, in which no mature oocyte is released, 
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occur more often in perimenopause than premenopause.
130-132
   The lack of ovulation is 
thought to result in sustained high levels of FSH.
131, 132
  Changes in bone marker 
expression can differ between ovulatory and anovulatory cycles.
10
  Future studies would 
benefit from measuring FSH levels to consider this factor into the analysis of BTMs 
changes over time in perimenopausal women.   
In addition to primary endpoints of bone health, we also measured secondary 
endpoints focused on quality of life. The first aspect of quality of life we examined were 
symptoms related to the menopausal transition.  The MENQOL questionnaire was 
utilized to detect changes in quality of life associated with vasomotor, psychosocial, 
physical, and sexual menopausal symptoms. Daily journal entries were examined to chart 
menstrual cycling. Melatonin has previously been examined for its use in the treatment of 
vasomotor symptoms, but no significant effects were identified.
133
  Our study confirms 
the lack of vasomotor effects as indicated by the lack of significant change in the 
MENQOL vasomotor domain score (Table 4). Interestingly, we did detect a significant 
improvement in subjective measures of physical menopausal symptoms with daily 
nocturnal melatonin supplementation.  Subjects taking melatonin also had fewer 
menstrual periods during the six- month study (Figure 12).  Taken together, these results 
suggest a role for melatonin in improving patient quality of life during the menopausal 
transition.  
Due to fluctuating hormone levels, perimenopausal women experience irregular 
and often heavy vaginal bleeding. Our study shows melatonin may influence the length of 
time between menstrual cycles, possibly indicating a restoration of normal cycling 
patterns. It has been hypothesized that melatonin may restore normal bleeding patterns in 
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early postmenopausal women.
83, 133
  In a double-blind randomized controlled trial, 
Secreto et al. found more postmenopausal women receiving melatonin treatment (3 mg 
orally for three months) reported menstrual flow or spotting compared to women who did 
not take melatonin.
133
  The authors speculate melatonin may resume menstrual flow in 
early postmenopausal women; however, the inclusion criteria for the study included 
women who had not had a menstrual period in the past six months. Some subjects may 
technically have been in perimenopause until one year had passed without menstruation.  
The inclusion of perimenopausal women could explain why some subjects experienced 
bleeding or spotting.  A study by Bellipanni et al. reported resumption of normal 
menstrual cycles including bleeding and duration in 12 postmenopausal women taking 3 
mg oral melatonin nightly.
83
  These women were all 1 to 2 years past their final menstrual 
period.  The restoration of normal bleeding patterns in these studies supports our findings 
that melatonin treatment may regulate menstrual cycling in perimenopausal women.  
Melatonin may play a role in the regulation of endocrine changes during perimenopause. 
 The hormonal imbalance in perimenopause is considered hyperestrogen relative 
to hypoprogesterone.
5
  When compared to premenopausal women, perimenopausal 
women have increased melatonin during the luteal phase, a time when progesterone is 
also high.
134
  Likewise, melatonin levels increase with progestin levels in premenopausal 
women taking a 3-phase contraceptive pill.
134
  While melatonin has a synergistic 
relationship with progesterone,
99, 134
 it has an inverse relationship with estrogen such that 
when estrogen levels are high melatonin levels are low.
101-104
    These relationships may 
be explained, in part, by evidence implicating melatonin in the modulation of ovarian 
function; however, the exact mechanisms are not well-understood.  Melatonin 
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concentrations in the ovary, specifically in preovulatory follicular fluid, are higher than in 
serum samples indicating a role for melatonin in the ovary.
90, 91
  In addition, in vitro 
experiments demonstrate the ability of melatonin to enhance progesterone secretion from 
stimulated human granulosa cells
94, 99
 and corpus luteum.
100
  Melatonin receptor mRNA 
transcripts
93, 94
 and binding sites
95
 have been discovered on human granulosa cells, 
suggesting melatonin may influence ovarian function through receptor-mediated events. 
A recent study investigated the impact of melatonin on serum progesterone levels in 
women with low luteal phase serum progesterone.
135
  Administration of 3 mg oral 
melatonin nightly during the luteal phase improved serum progesterone levels in 9 of 14 
patients; whereas, only 2 of 11 placebo patients had improved progesterone levels.
135
  
The interplay between melatonin and reproductive hormones points towards a possible 
role for melatonin in stabilization of the hormonal imbalances that characterize 
perimenopause.  By balancing the fluctuations in hormone levels, melatonin may relieve 
some of the more bothersome symptoms associated with perimenopause including 
irregular bleeding patterns as evidenced by the fewer number of menstrual periods 
experienced by women in the melatonin group (Figure 12).  Improvement of physical 
symptoms associated with perimenopause would enhance quality of life for women going 
through the menopausal transition. 
Analysis of baseline melatonin levels show more women in the melatonin group 
(11/13) to have daytime serum melatonin levels below 40 pg/ml compared to placebo 
(2/5).  Women in perimenopause undergo periods of high estrogen secretion
4
, which 
could possibly affect melatonin levels.  This idea is supported by an inverse relationship 
between estrogen and melatonin.
102
  Thus, the low melatonin levels in the melatonin-
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treated group could indicate higher estrogen levels, suggesting more women in the 
melatonin group may have been in a hyperestrogen state. Future studies could also 
measure estrogen to examine how melatonin levels may change with higher or lower 
estrogen levels. 
In addition to irregular bleeding patterns, perimenopause is often characterized by 
sleep disturbances.
6, 7
  Melatonin is well-known for its ability to regulate sleep patterns
47
; 
therefore, as part of our secondary endpoints, we examined the impact of melatonin on 
sleep quality.  Treatment with melatonin did not significantly change sleep quality as 
measured by the PSQI survey.  This survey is designed to identify “good” and “poor” 
sleepers.
116
  On the 0-21 PSQI score scale, both groups of subjects had a mean starting 
PSQI score around 5 (Table 3), indicating that the majority of the enrolled participants 
may have already been experiencing “good” sleep.  Therefore, small changes in sleep 
quality, which may have been evident to the subjects, may not have been captured with 
this specific sleep questionnaire.  As sleep quality was a secondary endpoint of this study, 
our measures relied on participant records to identify changes in sleeping patterns.  We 
found no change in the average number of hours slept per night with melatonin treatment 
(Figure 6); however, participants also kept a normal daily routine throughout the study.  
Thus, the number of hours of sleep may be more a product of normal scheduling rather 
than a lack of effect by melatonin.  A meta-analysis of studies examining the effects of 
melatonin on sleep found a significant reduction in sleep onset latency, increased sleep 
efficiency, and increased total duration of sleep with melatonin therapy as measured by 
objective sleep endpoints.  Interestingly, the authors discovered many studies that relied 
on subjective measure of sleep found melatonin had no efficacy, indicating objective 
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measures may be necessary to define small but significant changes in sleep quality.
81
  
Nevertheless, the fact that the majority of melatonin subjects correctly identified their 
treatment group based on reported improvements in sleep and well-being indicates 
melatonin may alleviate the sleep disturbances experienced by perimenopausal women.  
Melatonin may also improve blood pressure in perimenopausal women as 
evidenced by the decreasing trend in both systolic and diastolic blood pressure over the 
study period (Figure 14).  The exact mechanisms of how melatonin modulates blood 
pressure are not well-characterized but may involve antioxidant activity, activation of 
MT2 receptors on the coronary artery and aorta, and regulation of central nervous system 
areas involved in control of blood pressure.
113
  Nighttime melatonin administration has 
been shown to significantly decrease nocturnal systolic and diastolic blood pressure in 
healthy women.
136
   In this study, we selected women with blood pressure in the normal 
range as a change in blood pressure was not our primary endpoint.  Perimenopausal 
women with rising blood pressure my further benefit from melatonin supplementation in 
addition to its effect on physical symptoms of menopause.   
This study was designed as a pilot study to examine the impact of melatonin 
supplementation on bone health with secondary endpoints examining quality of life 
issues in perimenopausal women.  Limitations to this study include small sample sizes, a 
significantly older population of women in the melatonin group, and heterogeneity in 
terms of stage of perimenopause and prevalence of menopausal symptoms. Despite the 
small sample sizes in this study, we detected a significant improvement in MENQOL 
physical domain scores with nightly melatonin supplementation.  Staging of menopause 
can affect the perception of symptoms common in the menopausal transition.  In this 
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study, it is possible that women were in different stages of the perimenopausal transition 
(early vs late).
2
  Those just beginning perimenopause may have different perceptions of 
symptoms compared to women who have been in perimenopause for some time.  
Additionally, women may have had variable responses to the effects of melatonin 
depending on their hormone profile.  As relief of menopausal symptoms was not the 
primary outcome of this study, subjects were not stratified based on stage of menopause, 
degree of menopausal symptoms, or hormonal profile.  Thus, larger-scale studies with 
group stratification may further substantiate the findings of this study related to the 
effects of melatonin on quality of life issues in perimenopausal women.  Additionally, we 
utilized a dose of 3 mg of melatonin in this study.   As there are currently no published 
results regarding melatonin dosage and effects on bone, we chose a dose known to 
produce a physiologic effect on circadian rhythm.
110
   A larger dose may produce a more 
robust change in bone markers than was seen in this study.  Future studies should 
examine other dosages of melatonin to investigate how an increased dose may impact 
changes in bone markers.   
The main objective of this pilot study was to generate hypotheses and refine study 
methods for future investigations.  We were successful in recruiting perimenopausal 
women to participate in this study.  Retention of enrolled participants was high, most 
likely because of monthly follow-up phone calls and a lack of adverse effects. 
Recruitment strategies for future studies should focus on sources of publicity that allow 
more details of the study to be given such as newspaper articles in local newspapers. We 
did not find a significant change in biochemical markers of bone turnover with melatonin 
treatment. We did, however, find a trend in the ratio of NTX to OC, possibly indicating a 
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balancing of bone remodeling with treatment.  In order to better detect changes in 
markers of bone turnover, future studies should include measurement of several makers 
of both resorption and formation.  Serum samples should be taken in the early morning in 
fasting participants to minimize sources of variability due to circadian patterns and diet.  
Melatonin also improved quality of life scores related to physical symptoms of 
menopause.  Interestingly, we did not find an improvement of sleep patterns with 
melatonin as measured by the PSQI survey. Serum FSH levels should be measured to 
better classify participants as being in early or late perimenopause. The influence of 
melatonin on menstrual cycling could be further explored through more detailed 
questions in the daily journal entries. Information about the extent of menstrual bleeding, 
symptoms associated with menstruation like breast tenderness, and duration of the 
menstrual period would allow for more exploration into how melatonin influences 
menstrual cycling.  The use of activity watches (wrist actigraphy) in conjunction with 
sleep diaries may provide a more detailed account of sleep disturbances experienced by 
study participants allowing for more objective analysis of the ability of melatonin to 
improve sleep quality in perimenopausal women.  Overall, our study illustrates the 
potential for melatonin to enhance quality of life in perimenopausal women by reducing 
physical symptoms associated with the menopausal transition.  Melatonin may also 
protect women from bone loss by maintaining balance between osteoblast and osteoclast 
activity.  A more extensive, longitudinal study into the long-term effects of melatonin 
supplementation throughout the perimenopausal transition into menopause is warranted. 
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APPENDIX A 
Additional Standard Curves for Osteocalcin Immunoassays 
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Additional Standard Curves for NTX Immunoassays 
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APPENDIX B 
Monthly T-Scores – Placebo Group 
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Monthly T-Scores – Melatonin Group
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Monthly T-Scores – Melatonin Group (continued) 
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Bone Turnover Markers – Placebo Group 
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Bone Turnover Markers – Melatonin Treatment Group 
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Bone Turnover Markers – Melatonin Treatment Group (continued) 
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Melatonin Serum Levels at Baseline and Month 6 
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Blood Pressure Measurements – Placebo Group 
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Blood Pressure Measurements – Melatonin Treatment Group 
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Blood Pressure Measurements – Melatonin Treatment Group (continued) 
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